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INTRODUCTION 
              Carcinoma is the leading cause of premature death in the world. 
Due to the rapid advancement in cancer diagnosis and therapy, the life 
expectancy and survival rate of cancer patients have shown improvement. 
However, the overall clinical outcome of cancer is still unsatisfactory due 
to its high invasive and metastatic properties. In order to achieve 
therapeutic success in cancer patients, there is still room to develop new 
treatment strategies that target at various stages of tumour progression. A 
flurry of scientific investigations has identified angiogenesis as one of the 
important processes in cancer development.  Angiogenesis was found to 
promote tumour growth and metastasis. Therefore antiangiogenesis might 
be an effective cancer treatment strategy.  
Among several angiogenic activators, thymidine phosphorylase  
has been recognized as an important angiogenic protein that is frequently 
overexpressed within solid tumours. In recent years, emerging data 
provided convincing evidence that TP and its metabolic product, 2-deoxy-
D-ribose (2DDR) stimulate the secretion and/or expression of many 
angiogenic factors, such as MMPs and VEGF, which trigger a signalling 
cascade to induce endothelial cell migration, proliferation, elongation and 
sprouting. These events eventually lead to angiogenesis and cancer 
metastasis. Therefore, TP has been implicated as a potential target for the 
development of chemotherapeutic agents.[1] 
Thymidine phosphorylase[2-11] 
Thymidine phosphorylase (TP) was first discovered in 1954 as a 
key enzyme of the pyrimidine salvage pathway which catalyzes the 
conversion of thymidine and 2- α -deoxyuridine to their respective bases 
(thymine and uracil) and 2-α-D-deoxyribose-1-phosphate (2DDR-1P).  
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Figure 1 :Enzymatic reaction catalyzed by TP.TP catalyzes the reversible 
conversion of thymidine to thymine and 2DDR-1P.TP also has 
deoxyribosyltransferase activity by which the deoxyribosyl moiety is 
transferred from one pyrimidine base to another, resulting in the formation 
of a new nucleoside. 
This reaction is reversible; however, the most important metabolic 
function of TP is catabolic. TP also has deoxyribosyl transferase activity by 
which the deoxyribosyl moiety is transferred from a pyrimidine nucleoside 
to another pyrimidine base, resulting in the formation of a new pyrimidine 
nucleoside. Besides natural 2 α-deoxynucleosides, TP also recognizes 
several pyrimidines or pyrimidine nucleosides with antiviral and antitumoral 
activity, such as 5-(E)-(2-bromovinyl)-2α-deoxyuridine (BVDU), 5-
trifluorothymidine (TFT), 5-fluorouracil (5FU), and 5-fluoro-5 α-
deoxyuridine (5αDFUR), an intermediate metabolite of Capecitabine, 
which is clinically used against metastatic breast and colon cancer. 
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               In 1987, a so-called ‘‘new’’ protein was isolated from human 
blood platelets. This protein was believed to stimulate endothelial cell 
growth because it increased the [3H]-thymidine uptake and was therefore 
named ‘‘platelet-derived endothelial cell growth factor (PD-ECGF).’’ PD-
ECGF was also shown to induce endothelial cell migration in vitro and 
angiogenesis in vivo.  A few years later, it was reported that recombinant 
PD-ECGF has TP activity. Moreover, analysis of the amino acid sequence 
of both proteins revealed that PD-ECGF and TP are identical. This leads 
to the conclusion that the observed increased thymidine uptake was an 
artifact, caused by the TP activity of PD-ECGF.  
A third role for TP has also been described and in this context TP is 
called gliostatin. In 1992, gliostatin was extracted from human 
neurofibroma. This protein inhibits the growth of both astrocytes and glial 
tumor cells. Thus, TP, PD-ECGF and gliostatin are all synonyms that refer 
to the same, identical protein.  
STRUCTURE OF TP 
In the mid-1970s TP was purified from both Escherichia coli and 
Salmonella typhimurium. Several years later, human TP was extracted 
from the amniochorion. The amino acid sequence of TP is highly 
conserved during evolution. For example, human TP shares 39% 
sequence identity with E. coli TP. 
TP functions as a homodimer consisting of two identical subunits 
(Fig. 2), with a dimer molecular mass ranging from 90 kDa in E. coli to 110 
kDa in mammals. Detailed structural information on TP was first provided 
in 1990 by Walter et al. who solved the crystal structure of E. coli TP. This 
analysis revealed that each subunit contains a large mixed α-helical and β-
sheet domain (α/β domain) separated from a smaller α-helical domain (α-
domain) by a large cleft. The active site consists of the thymine-binding 
site in the α-domain and the phosphate-binding site across the cleft in the 
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α/β domain. The finding that both sites were about 8Å apart immediately 
suggested that a hinge motion of one domain relative to the other was 
necessary to generate a closed conformation of the enzyme. 
 
Figure 2. Ribbon representation of human TP showing the dimeric 
structure and a detail of the active site (boxed) containing either the  
TP inhibitor (C atoms in orange) or the thymine product (C atoms in white).  
It took several more years to have the structure of human TP solved 
because many crystallization trials failed to produce well-diffracting 
crystals. Thus, Spraggon et al. reported crystals of human TP for which, 
despite using a synchroton X-ray source, diffraction was limited to 3.5Å 
resolution. Finally, in 2004, Norman et al. successfully solved at 2.1Å 
resolution the structure of human TP in complex with the small and potent 
inhibitor 5-chloro- 6-[1-(2-iminopyrrolidinyl)methyl] uracil (TPI).  
In 2006, El Omari et al. managed to determine the structure of 
unproteolyzed human TP at 2.3 Å resolution with the aid of the small-
molecule inhibitor KIN59, which helped to obtain good quality diffracting 
crystals. In Figure 2, a ribbon representation of human TP is shown, 
clarifying the dimeric structure and a detail of the active site containing 
either the inhibitor TPI or the thymine product. As kinetic studies of E.coli 
TP have shown that phosphate is the first substrate that binds to TP 
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whereas 2DDR-1P dissociates last from the enzyme, this finding suggests 
that after product release, thymine is able to reassociate with the 
unliganded enzyme and stabilize the closed conformation, which may 
explain the mechanism of noncompetitive product inhibition. 
The Physiological Role of TP 
TP is found in many normal tissues and cells, with high levels in 
macrophages, stromal cells, glial cells, reticulocytes, some epithelial 
tissues of the digestive tract (oesophagus and the rectum), salivary gland, 
brain, bladder, spleen, lymph, and the lungs. Within the cell, TP is present 
in both the cytoplasm and the nucleus. Blood platelets are one of the 
richest sources of TP, which suggests a role for the enzyme in wound 
healing. TP activity is also detected in plasma and serum, where its 
presence is probably due to blood platelet damage or cell turnover. 
Furthermore, TP plays an important role in the female reproductive cycle. 
Large quantities of TP are found in the placenta, where two alternative 
forms of the protein are detected.  
TP Overexpression in Cancer 
Thymidine phosphorylase is a highly expressed protein in many 
solid human tumours, and the level of expression is associated with 
tumour neovascularization, invasiveness and metastasis. TP is 
predominantly expressed in hypoxic regions of solid tumours, promoting 
tumour growth by angiogenesis, metastasis and suppressing apoptosis. 
TP is also known as platelet-derived endothelial cell growth factor (PD-
ECGF), a novel angiogenic protein, distinct from other angiogenic growth 
factors, since it exerts its actions through its enzymatic activity and 
inhibitors prevent the angiogenic activity of TP. The dephosphorylated 
product, D- 2-deoxyribose  has been shown to have chemotactic activity in 
vitro and angiogenic activity in vivo and is considered to play a key role in 
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the invasiveness and metastasis of TP expressing solid tumours . Since 
TP is over-expressed in tumours, the protein is an attractive cancer 
chemotherapy target for selective inhibition of TP-dependent angiogenesis 
and subsequent inhibition of tumour growth. In addition, specific inhibitors 
of human TP could also enhance the efficacy of thymidine  
analogues such as 5-fluoro-2α-deoxyuridine and 5-iodo-2α-deoxyuridine, 
which would no longer be metabolized and inactivated by TP. The 
classical TP inhibitors include 6-amino-5-bromouracil(6A5BU) and  
7-deazaxanthine (7-DX )  which was the first purine derivative to display 
inhibition of both E.coli TP and angiogenesis in a chorioallantoic 
membrane assay .Indeed, a potent inhibitor of TP, 5-chloro-6-[(2-
iminopyrrolidin-1-yl)methyl]uracil  (TPI) entered clinical trials in 
combination with 5-trifluoromethyl- 2α-deoxyuridine as an orally available 
anticancer treatment under the name of TAS-102. 
Increased TP expression in tumor tissues compared to 
corresponding nonneoplastic tissue was found in breast, bladder, gastric, 
colorectal, lung, esophageal, and cervical cancers but not in cancers of the 
liver,common bile duct, and the thyroid. TP expression is not only 
upregulated in solid tumors, elevated levels of TP were also observed in 
lymph nodes of patients with classical Hodgkin lymphoma where TP levels 
increased with disease progression.  These data identify TP as a potential 
target for the immunotherapy of hematological tumors. 
Numerous studies on cancer patients have examined the relation 
between TP expression and microvessel density, tumor grade, stage, 
metastasis and prognosis. In these studies TP was measured by RT-PCR, 
immunohistochemistry, or by activity assays. Generally, TP expression is 
correlated with higher microvessel density, higher tumor stage and more 
metastasis. An association of TP with tumor grade is evident in bladder, 
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cervical, and renal cell cancer, but not in the other investigated cancers. 
Furthermore, in most cases, TP appeared to be associated with poor 
prognosis, although there are conflicting reports for some cancers. For 
example, seven of the nine studies on colon cancer reported a significant 
correlation between TP and bad prognosis, while Saito et al. demonstrated 
that TP is associated with good prognosis. These discrepancies might be 
caused by differences in the histological type of cancer, stage (early 
versus advanced stage of disease), number of patients examined, assay 
for TP and different methodology for the evaluation of the 
immunohistochemistry results. 
Tumors are heterogeneous tissues consisting of unknown variable 
contributions of tumor, stromal, and infiltrating cells. Besides tumor cells, 
also endothelial cells, fibroblasts, lymphocytes and especially tumor-
associated macrophages (TAM) express TP. TAM are thought to play a 
key role in stimulating tumor growth and metastasis through the production 
of various growth factors, proteinases, chemokines, and cytokines. High 
levels of TP have been demonstrated in TAM of melanoma, gastric, 
glioblastoma, breast, colon, astrocytic,uterine, endometrial and prostate 
cancer. In gastric adenocarcinoma, astrocytic tumors, breast, and uterine 
endometrial cancer, TP expressed in macrophages has been suggested to 
be correlated with microvessel density and to play an important role in 
tumor invasiveness. 
            Elevated TP levels are not only found in the tumor tissue but also 
in the plasma of cancer patients. Already in 1977, Pauly et al. 
demonstrated that cancer patients had much higher TP activity in the 
plasma than healthy individuals. More recent data indicate that plasma TP 
concentrations in cancer patients may have a prognostic value. In uterine 
cervical cancer high serum TP levels correlate with clinical stage, tumor 
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size, lymph node metastasis and an extremely poor prognosis. High TP 
concentrations in the blood are also associated with depth of tumor 
invasion and poor response to treatment in patients with esophageal 
squamous cell carcinoma. Furthermore, in patients with colorectal 
cancers, the TP serum level is suggested to be a novel marker to predict 
occurrence of hematogenous metastasis. 
The inhibition of TP may result in reduction of tumor growth and 
metastasis and it also potentiates the antiproliferative effect of  
nucleoside drugs such as 5-(E)-(bromovinyl)-2α-deoxyuridine, 2α-deoxy-5-
trifluoromethyluridine, 2α-deoxy-5-iodouridine and 5-fluoro-2α-
deoxyuridine which are substrates of TP. As follows from the survey of 
literature, the inhibition of TP represents a promising target in cancer 
chemotherapy. Schiff bases of 3 formylchromone has been already 
reported as thymidine phosphorylase inhibitors. 
TP AND TUMOR DEVELOPMENT[12-16] 
A.  Role of TP in Angiogenesis 
Angiogenesis is the formation of new blood vessels from preexisting 
vessels and it is essential for organ growth and repair. However, it is well 
known that this is a vital step in the process of cancer growth. Thus, 
angiogenesis inhibitors are believed to be potential candidates for blocking 
cancer growth.  
In particular, thymidine phosphorylase (TP) is a pro-angiogenic 
factor which catalyzes the reversible phosphorolysis of thymidine into 
thymine and 2α-deoxy-D-ribose 1-phosphate.The 2α-deoxy-D-ribose 1-
phosphate undergoes further dephosphorylation to produce 2-deoxy-D-
ribose which stimulates the secretion of vascular endothelial growth factor 
(VEGF). VEGF activates a number of processes including endothelial cells 
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for secretion of matrix metalloproteinases, proliferation, and migration of 
endothelial cells to tumor tissue. These actions result in fast generation of 
new blood vessels and cancer metastasis. 
1.  TP stimulates endothelial cell migration 
The molecular mechanisms through which TP and 2DDR stimulate 
endothelial cell migration in vitro are not completely understood. Hotchkiss 
et al revealed that TP and 2DDR affect endothelial cell migration through 
activation of integrins and their downstream signaling pathways. In human 
umbilical vein endothelial cells (HUVEC), it was shown that both TP and 
2DDR stimulate the formation of focal adhesions and the phosphorylation 
of tyrosine 397 of focal adhesion kinase (FAK). FAK is a nonreceptor 
protein–tyrosine kinase that is recruited to focal adhesions by integrin. 
Thus, FAK plays an important role in endothelial cell attachment and 
migration.Hotchkiss et al. also demonstrated that VEGF, TP, and 2DDR all 
stimulate HUVEC migration, although through different integrins.  
2. TP induces the expression and/or secretion of other 
 angiogenic factors 
            Various studies have demonstrated that TP and 2DDR promote the 
expression and secretion of several angiogenic factors.  Human bladder 
carcinoma cells transfected with TP (RT112-TP) secrete higher amounts 
of VEGF, interleukin-8, and MMP-1 than mock transfected RT112 cells in 
the presence of thymidine. RT112-TP cells incubated with thymidine also 
showed an elevated expression of heme oxygenase-1 (HO-1), HO-1 is an 
enzyme that catalyzes the degradation of heme to carbon monoxide, iron, 
and biliverdin. The expression of HO-1 can be induced by hypoxia, 
cytokines, and several angiogenic factors such as VEGF and stromal cell 
derived factor-1 (SDF-1). Recent data indicate that HO-1 also possesses 
proangiogenic properties: it promotes endothelial cell proliferation, protects 
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endothelial cells from apoptosis, and induces the secretion of several 
angiogenic mediators. Brown et al. suggested that 2DDR is a strongly 
reducing sugar that may generate oxygen radical species during the early 
stages of protein glycation. It was hypothesized that 2DDR binds to an 
amino group (preferentially at a lysine, arginine or the N-terminal amino 
acid) of a protein during a nonenzymatic reaction, the so-called Maillard 
reaction. This may lead to the formation of a Schiff base, which can then 
rearrange to an α-hydroxyketone. This unstable reaction intermediate 
autoxidizes during which reactive free oxygen radicals are produced. 
Thus, through the formation of 2DDR, TP may induce oxidative stress in 
TP-overexpressing tumor cells causing these cells to secrete angiogenic 
factors, such as VEGF.  
B.  TP Induces Metastasis 
TP was found to increase the metastatic potential of several 
experimental and human tumors. Moreover, in various cancers high TP 
expression correlates with metastasis. Takao et al. demonstrated that TP-
expressing KB carcinoma cells show more basement membrane invasion 
than their mock-transfected counterparts. The stimulation of metastasis by 
TP-overexpressing cells could be dramatically inhibited by the TP inhibitor 
TPI or by 2-deoxy-L ribose (2DLR), a stereoisomer of 2DDR.  
C. TP Protects Cancer Cells Against Apoptosis 
            A correlation between TP expression and apoptosis was first 
demonstrated in vitro by using human epidermoid carcinoma KB cells. KB 
cells transfected with TP (KB/TP) were resistant to hypoxia-induced 
apoptosis. This advantage was abrogated when the cells were treated with 
TPI, which inhibits the enzymatic activity of TP, leading to the conclusion 
that the enzymatic activity of TP is indispensable for protection against 
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hypoxia-induced apoptosis.  Also the metabolites of the TP reaction, 
2DDR and thymine, partially prevented hypoxia-induced apoptosis in KB 
cells. 
TP INHIBITORS[17-22] 
In 1971, Judah Folkman postulated that tumor growth is 
angiogenesis-dependent and that tumor development and metastasis 
could be abolished by blocking the tumor blood supply. Currently, anti-
angiogenic drugs, such as the VEGF-antibody Bevacizumab (Avastin) and 
the kinase inhibitors Sorafenib (Nexavar), and Sunitinib (Sutent) are being 
used in cancer treatment while dozens of other anti-angiogenic molecules 
are evaluated clinically. However, the benefits from these anti-angiogenic 
therapies are at the best temporary and mostly followed by resistance 
development of the tumor. Although tumor resistance may be caused by 
various mechanisms such as poor pharmacokinetics, limited drug uptake, 
increased drug efflux, and mutation of the target proteins, tumor resistance 
may also be caused by circumvention of the angiogenic blockade by 
activation and/ or upregulation of alternative pro-angiogenic pathways in 
the tumor. For example, a study on glioblastoma patients treated with the 
VEGF receptor inhibitor cedinarib (Recentin) showed that the tumors 
evaded the anti-angiogenic therapy by upregulating the angiogenic 
fibroblast growth factor-2 (FGF-2) and stromal cell derived factor-1α (SDF-
1α). Therefore, there is an urgent need to develop anti-angiogenic drugs 
directed at different angiogenic targets. 
            As TP plays a fundamental role in cancer angiogenesis, many 
laboratories have tried to synthesize potent TP inhibitory drugs. Some of 
these molecules have been tested preclinically and clinically, but currently 
no product has been approved  yet  for clinical use.  
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A. Pyrimidine Analogues 
            For more than 30 years the only compounds known to inhibit TP 
were uracil derivatives, such as 6-aminothymine (6AT) and 6-amino-5-
bromouracil (6A5BU). These molecules have 50% inhibitory concentration 
(IC50) values against the enzyme in the submicromolar range. When it 
became clear that TP is not only an enzyme involved in the nucleoside 
salvage pathway but is also implicated in angiogenesis, numerous 
laboratories aimed at synthesizing more potent TP inhibitors. 
            In 2000, Fukushima et al. identified ‘‘5-chloro-6-[1-(2 
iminopyrrolidinyl) methyl] uracil hydrochloride (TPI)’’ (Fig. 3), the most 
potent inhibitor of human TP so far, with an IC50 value of 35 nM. This 
molecule was shown to abrogate several biological actions of TP. For 
example, TPI inhibited TP-induced angiogenesis in the mouse dorsal air 
sac assay. It also significantly reduced the tumor growth rate and 
microvessel density and increased the apoptotic index of 
KB/TPxenografted tumors. Furthermore, oral administration of TPI 
suppressed macroscopic liver metastasis of highly metastatic KB/TP cells 
and also the level of human β -globin as a molecular marker of 
micrometastasis in the livers of the mice. The fact that TPI is orally bio-
available and has a strong nanomolar inhibitory activity against TP 
suggests that this molecule might be a promising antitumor agent. 
N
H
NH
O
CH3
NH2O N
H
NH
O
Br
NH2O
6-Amino Thymine 6- Amino 5-Bromo Uracil
OO
OH
OH
N
N
NH
N
O
KIN 59
N
NH
N
NH.HCl
Cl
O
XO directed
prodrug of TPI
 
O 
TPI 
Introduction 
 
 
 
Department of Pharmaceutical Chemistry  13 
N
H
NH
N
H
O
O
NH
N
H
N
P
OH
O
OH
O
O
7
-
 Deazaxanthine TP 65  
OO
OH
OH
N
N
NH
N
O
KIN 59
N
NH
N
NH.HCl
Cl
O
XO directed
prodrug of TPI  
Figure 3. Chemical structure of some illustrative inhibitors of TP. 
B.  Purine Analogues 
Balzarini et al described 7-deazaxanthine (7-DX) (Fig. 3) as the first 
purine derivative with inhibitory activity against a pyrimidine nucleoside 
phosphorylase (i.e. TP). The three-dimensional structure of E. coli TP was 
used for the rational modelling and design of 7-DX, which can be regarded 
as a pyrimidine at which a second ring was added to create extra 
stabilization. 7-DX not only efficiently inhibited the enzymatic activity of TP; 
it was also able to prevent neovascularization in the CAM assay. The 
available crystal structure of E. coli TP has also led to the rational design 
of compounds that interact both with the thymine and the phosphate-
binding site, the so-called multisubstrate analogue inhibitors of TP. These 
types of molecules consist of a base, interacting with the nucleoside-
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binding site and a phosphonate moiety that may bind to the phosphate-
binding site. The distance between the thymine and the phosphate-binding 
site of E. coli TP is estimated to be around 10A˚, therefore the thymine and 
the phosphonate moiety of these novel inhibitors were linked to each other 
with a spacer of 6–9 methylene entities. These compounds interact with 
both substrate-binding sites, and thus ‘‘freeze’’ the enzyme in an open, 
inactive conformation. TP65, which contains an alkyl phosphonate moiety 
covalently linked to 7-DX (Fig. 3), is such a multisubstrate inhibitor of TP, 
with an IC50 value in the micromolar range. This molecule could also 
abrogate biological activities of TP, such as angiogenesis in the CAM 
assay and the formation of microvascular sprouts from endothelial cell 
aggregates in a fibrin gel. 
Another purine derivative that inhibits TP is 5α-O-tritylinosine 
(KIN59). KIN59 consists of a purine base (hypoxanthine), a ribose sugar 
and a trityl group at the 5α-position of the ribose. The trityl group of KIN59 
has proven to be crucial for its inhibitory activity against TP and its anti-
angiogenic effect in the CAM assay. KIN59 is in several ways a very 
unusual TP inhibitor. In the CAM assay, KIN59 not only prevented the 
formation of new blood vessels but also promoted the degradation of small 
pre-existing immature blood vessels. This effect was not due to unspecific 
cell toxicity. Furthermore, in contrast to all previously described TP 
inhibitors, this molecule does not compete with the natural substrates for 
binding to either the nucleoside or the phosphate-binding site of TP, but 
interacts with a new, yet unknown, allosteric site of the enzyme in a non-
competitive fashion. 
C.  Prodrugs of TP Inhibitors 
Reigan et al. have explored a xanthine oxidase (XO) prodrug 
strategy. XO activity and expression are increased in hypoxic conditions. 
Moreover, increased XO activities are found in colorectal and prostate 
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tumors as compared to their corresponding normal tissues. Therefore, 2’-
nitro prodrugs of potent 2’-aminoimidazolyl TP inhibitors were developed. 
These prodrugs may become selectively activated by XO in the tumors 
and thus may exert their TP inhibitory activity specifically within the 
hypoxic regions of the tumors. Also XO sensitive prodrugs of 6A5BU, 7-DX 
and TPI have been synthesized. The in vivo efficacy of these prodrug 
molecules remains to be investigated. 
 
 
 
 
 
Literature Review 
 
 
 
Department of Pharmaceutical Chemistry  16 
LITERATURE REVIEW 
SCHIFF BASES OF 3 FORMYL CHROMONE 
As Thymidine phosphorylase inhibitors 
K.M Khan., et al. synthesized  a series of Schiff bases of 3 formyl 
chromone and evaluated their thymidine phosphorylase inhibitory 
activity.[3]  
                                 O
O
N
OCH3
CH3
 
 3-{[(3-Methoxy-4-methylphenyl) imino] methyl}-4Hchromen- 4-one 
exhibited the highest inhibitory activity.                    
 
As anti cancer agents 
 
Shadia et al., synthesized Schiff base derived from 3-
formylchromone and benzohydrazide  and its Ni(II), Zn(II), Ru(II), Ru(III), 
Pd(II), Pt(II) and Ag(I) complexes have been tested as anticancer agents 
against the human breast cancer (MDAMB 231) and human ovarian 
cancer (OVCAR-8) cell lines.[23] 
                                
O
O
O
N
NH
 
 The Ag(I)  complex showed promising efficacy. 
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Osowole et al., synthesized Mn(II), Co(II), Ni(II), Cu(II) and Pd(II) 
complexes of the Schiff bases obtained by  condensation of 3-formyl-6-
methylchromone and 4- methyl thioaniline and evaluated its cytotoxic 
activity against  both MCF-7(human breast adenocarcinoma) and HT-29 
(colon carcinoma) cells.[24] 
                              
O
N
S
CH3
O
CH3
 
The cytotoxic study shows that the Cu(II) complex has the best in-
vitro anticancer activity against both MCF-7 (human breast 
adenocarcinoma) and HT-29 (colon carcinoma) cells, with IC50 values of 
9.78 μM and 17.02 μM respectively. 
Kavitha et al., synthesized Pd(II) complexes of 3-formyl chromone 
Schiff bases and  the  cytotoxicity of complexes  was tested on three cell 
lines( murine macrophage cell line Raw 264.7, human breast cancer cell 
line MCF-7 and human colon carcinoma cell line (COLO 205).[25] 
O
O N
N
OH
 
Among all complexes pyridine ring containing complexes  are potent. 
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DNA binding studies 
Farukh et al., synthesized new chromone Schiff base organotin(IV) 
complexes {dimethyltin dichloride, diphenyltin dichloride and triphenyltin 
chloride}. The in vitro DNA binding profile of complexes was carried out by 
absorption, fluorescence spectroscopy and viscosity measurements. [26] 
                          O
O
CH
N
CH2
CH2
OH
 
The corroborative results of DNA binding studies revealed that the 
complexes  exhibit electrostatic mode of binding preferably via oxygen of 
sugar-phosphate backbone of DNA helix. 
Ju Wang  et al.,  synthesized  novel 6-ethoxy chromone-3-
carbaldehyde benzoyl hydrazone  and its Ln(III) complexes, [Ln= Sm (1), 
Eu (2), Gd (3), Tb (4)].  The DNA-binding properties of the Eu(III) and Sm 
(III)  complexes were investigated using UV Vis absorption spectroscopy, 
fluorescence spectroscopy and  viscosity measurement. [27] 
O
N
NH
O
H3CH2CCO
O
 
 All the experimental evidences indicate that the two complexes can 
bind to CT-DNA via an intercalation mechanism. 
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Yong Li et al., reported the synthesis of  3-carbaldehyde chromone 
thiosemicarbazone  and its Copper (II), Zinc (II) and Nickel (II) complexes . 
Interactions of ligand and Cu(II), Zn(II) and Ni(II) complexes with DNA 
were investigated by spectral and viscosity studies.[28] 
O
O N
NH
NH2S  
 DNA binding studies indicate that the investigated compounds bind 
to DNA via an intercalation binding mode and Zn(II) complex binds to DNA 
most strongly. 
Wang BD et al.,  reported the synthesis of  a new ligand, 6-hydroxy 
chromone-3-carbaldehyde-(2′-hydroxy) benzoyl hydrazone  by 
condensation of 6-hydroxy-3-carbaldehyde chromone (CDC) with 2-
hydroxy benzoyl hydrazine along with its  four rare earth Ln(III) complexes 
[Ln = La(1), Sm(2), Dy(3), Eu(4)].  Spectrometric titration, ethidium 
bromide displacement experiments, and viscosity measurements indicate 
that Eu(III) complex and ligand, especially the Eu(III) complex, strongly 
bind with calf-thymus DNA, presumably via an intercalation mechanism.[29] 
                                           
O
N
NH
O
O
OH
OH  
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As carbonic anhydrase inhibitors. 
           Luca Puccetti et al., synthesized a series of Schiff  bases  by 
reaction of 3- formyl-chromone or 6-methyl-3-formyl-chromone with 
aromatic sulfonamides such as sulfanilamide, homosulfanilamide, 4-
aminoethyl-benzene sulfonamide, a pyrimidinyl-substituted sulfanilamide 
derivative, sulfaguanidine and 4-amino-6-trifluoromethyl-benzene-1,3-
disulfonamide. The zinc complexes of these sulfonamides have also been 
obtained. The new derivatives and their Zn(II) complexes were 
investigated for the inhibition of four physiologically relevant isozymes of 
carbonic anhydrase : the cytosolic isoforms I and II, as well as the tumor-
associated,  transmembrane isozymes CA IX and XII.[30] 
 
                                  
OR
N
SO2
R'HN
O
R= H, Me
R' = H, C(=NH)NH 2  
Except for the sulfaguanidine-derived compounds which were 
devoid of activity against all isozymes, the other sulfonamides and their 
metal complexes showed interesting inhibitory activity. 
As antimicrobial agents 
Patil et al., synthesized Schiff bases of 7-hydroxy-3-formyl 
chromen-4-one. All the synthesized compounds were evaluated for 
antimicrobial activity against both gram positive and gram negative 
organisms. [31] 
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O
O N
NH
NO2
NO2
OH
 
                   The Schiff base synthesized from 2,4-dinitro phenyl hydrazine  
have shown the significant antimicrobial activity. 
 
Kavitha et al., synthesized a series of Co(II) complexes of formyl 
chromone Schiff bases and the ligands and Co(II) complexes were tested 
against bacterial species Proteus vulgaris, Staphylococcus aureus, 
Klebsiella pnuemoniae, Bacillus subtilis and Candida albicans (fungi).[32] 
                                    
O
O
N
COOH
 
Co(II) complex of 2-((4-oxo-4H-chromen-3-yl)methylneamino) benzoic acid 
showed good activity against all bacteria and fungi strains. 
  
            Sharad et al., synthesized a series of Schiff bases derived from 3-
formyl chromones and various aromatic aniline in aqueous media with 
microwave as an energy source. The newly synthesized compounds were 
tested for antimicrobial activity against bacterial strains Bacillus subtilis, 
Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli 
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.[33] 
O
N
R3
R2
R1
R5
R4
O
                      
a
b
c
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f
g
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H H H H 
H 
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H 
H 
H 
H 
H 
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H 
H 
H 
H 
H 
H 
H 
Cl 
Cl Cl 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
CH3 
CF3 
CF3 
CF3 
Cl 
OCH 3  
Schiff bases showed good to excellent antimicrobial activities 
against various bacterial and fungal strains. 
           Gyana et al., synthesized a series of Cu(II) , Ni(II) , Co(II) , Mn(II) 
and Zn(II) complexes  from the schiff base ligand  2-[(4-oxo-4H-chromen-
3yl) methyleneamino] benzoic acid , which is synthesized by the reaction 
between chromone-3-carbaldehyde and o-amino benzoic acid.  The ligand 
and its complexes were screened   for anti bacterial activity against E.coli, 
L.bacillus, B.subtilis and S.aures.[34] 
 
O
O
N
HOOC
 
The metal complexes showed potent anti bacterial activity. 
                      Laxma Reddy et al., synthesized Ni(II) and Zn(II) 
complexes from tridentate 3-formyl chromone Schiff bases with 2-amino 
thiophenol, 2-amino phenol, 2- amino benzoic acid and 2-amino 3-hydroxy 
pyridine. The synthesized ligands and metal complexes were   tested 
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against bacterial species Proteus vulgaris, Staphylococcus aureus, 
Klebsiella pnuemoniae, Bacillus subtilis and Candida albicans (fungi).[35] 
 
                                               
O
O
N
N
OH
  
Zn(II)  complex of 3-((3-hydroxypyridin-2-ylimino)methyl)-4H-chromen-4-
one showed good activity against all bacteria and fungi strains. 
 
Santosh et al., synthesized chitosan-chromone derivative gels   by 
reacting chitosan with chromone-3-carbaldehyde, followed by solvent 
exchange, filtration and drying by evaporation. The presence of free 
reactive amino groups leads to the possibility of forming a Schiff base of 
chitosan with chromone-3-carbaldehyde. The chitosan-chromone 
derivative were evaluated for antimicrobial activity against E.coli[36] 
O
O
CH
OO
OH
O
 
 
N
OH
n
 
The chitosan-chromone derivative had a dose-dependent 
antimicrobial activity against E. coli . 
           Ibrahim et al., synthesized some new heterocyclic schiff bases 
containing 1,2,4-triazole or 1,2,4-triazine derivatives combined with 
chromone moiety via the reaction of thiocarbohydrazone  with some 1,2-
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bifunctional electrophiles. The newly synthesized compounds were 
screened for their antimicrobial activity.[37] 
                                     O NH2
N
O
N NH
NH
S
Ph
 
                  Tudor Rosu et al., synthesized coordination compounds of 
Cu(II), VO(II), Ni(II), and Mn(II) with the schiff base obtained through the 
condensation of  4-amino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one with 3-
formyl-6-methyl-chromone and evaluated the in vitro antibacterial activity 
against Staphylococcus aureus , Klebsiella pneumonia , Escherichia coli, 
and Pseudomonas aeruginosa.[38] 
O
O N
N
N
CH3
CH3
O
CH3
 
 The quantitative antimicrobial activity test results proved that both 
the ligand and complex combinations have specific antimicrobial activity, 
depending on the microbial species tested. 
C. Anitha et al., synthesized Azo-Schiff-base complexes of VO(II), 
Co(II), Ni(II), Cu(II) and Zn(II) derived from  the condensation of 5-(4-
chloro-phenylazo)-2-hydroxy benzaldehyde, 3-formylchromone and p-
phenylene diamine. The ligands and their metal complexes were tested for 
their inhibitory effects on the growth of bacteria S. aureus, E. coli, S. 
enteric typhi, B. subtilis and fungus C. albicans.[39] 
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N
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             The Cu(II) and Zn(II) complexes showed  greater antibacterial 
activity and Co(II), Ni(II) and Zn(II) complexes showed greater antifungal 
activity for C. albicans. 
Zahid H. Chohan et al.,  synthesized Co(II) complexes of Schiff 
bases derived from 3,5-dichloroformylchromone and  aryl hydrazide. The 
ligands and their Cu(II) complexes were screened for their in-vitro 
antibacterial activity against four Gram-negative (Escherichia coli, 
Pseudomonas aeruginosa, Salmonella typhi, Shigella flexneri) and two 
Gram-positive (Bacillus subtilis, Staphylococcus aureus) bacterial 
strains.[40] 
                                        
O
N
NH
O
OR
Cl
Cl
 
R= C6H5OH, C6H5Br, C6H5Cl, C6H5NH2, N , 
N
 
The activity against all the Gram-negative and Gram-positive 
species was increased by coordination of the ligands with the Cu(II) metal 
ion. 
As anti inflammatory  agents 
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Khalid et al., synthesized  a series of Schiff bases of 3 formyl 
chromone .The synthesized compounds were evaluated for anti 
inflammatory activity by using  various in vitro and in vivo assay models.[41] 
O
O
NR
 
R = 
NH2
O
CH3      showed the highest activity. 
As antioxidants 
Kavitha et al., synthesized Pd(II) complexes of 3-formyl chromone 
schiff bases and  the antioxidant activity of Pd(II) complexes were 
evaluated using DPPH free radical scavenging method.[25] 
                        
O
O
N
HOOC
 
Pd(II) complex of 3-((2 -hydroxyphenylimino) methyl)-4H-chromen-
4-one showed activity comparable to standard. 
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SCHIFF BASES OF 2- AMINO  5 -ARYL 1,3,4 THIADIAZOLE 
AS ANALGESIC 
Alok et al., synthesized schiff bases of 2-amino-5-aryl-1,3,4-
thiadiazole derivatives  with different aromatic aldehyde. All the 
compounds were evaluated for their analgesic activity against swiss albino 
mice using hot plate method.[42] 
R
N
N
S
N
R
1
 
R= OCH3, OH, Cl, N(CH3)2  ;    R1 = OH  showed promising analgesic 
activity. 
As anthelmintic 
Bijo et al.,synthesized some Schiff bases of 5-phenyl substituted, 
2-amino 1, 3, 4 thiadiazole derivates and  anthelmintic activity of the 
synthesized  compounds were investigated. Parameters under study were 
mean paralysis and mean lethal time in Pheretima posthuma.[43] 
R3
R2
R1
N N
S
N
R4
R5
 
 
 All the compounds showed significant anthelmintic activity. 
As anti inflammatory agent 
      R1 R2 R3 R4 R5 
OH H H H Cl 
OH NO2 NO2 H Cl 
OCOCH3 H H H Cl 
H H H H H 
H NO2 H H Cl 
H NO2 H OH H 
H NO2 H H H 
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Alok et al., synthesized Schiff bases of 2-amino-5-aryl-1,3,4-
thiadiazole derivatives with different aromatic aldehyde and the 
compounds were evaluated for their anti-inflammatory activity against 
Wister albino rats by Carrageenan induced paw edema method.[42] 
R
N
N
S
N
R
1
                       
                
As antioxidants 
Abbas et al., (2012) synthesized  a series of Schiff's bases 
containing 1,3,4-thiadiazole (2,5-di(N-substitutedbenzylideneamino)- 1,3,4-
thiadiazole)  and the antioxidant properties were measured using the metal 
ions (Fe+3, Cu+2), Ferrozine and 2,9-dimethyl-1,10-phenanthroline 
(neocuproine).[44] 
S
N
N
N
N
R
R
 
R=  4- OH showed significant activity. 
 
 
 
As anti tubercular agents 
R=OH R’=OH 
R=Cl R’=OH 
R=OCH3 R’=NO2 
R=N(CH3)2 R’=NO2 
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Sevim et al., synthesized a series of new Schiff bases through the 
condensation reaction of 1,3,4- thiadiazoles containing an aromatic 
primary amine and 3-hydroxybenzaldehyde, salicylaldehyde, 5-
nitrofurfuraldehyde or 3-nitrobenzaldehyde. The synthesized compounds 
screened for antituberculosis activity against Mycobacterium tuberculosis 
H37Rv using BACTEC 460 radiometric system.[45] 
                        
N
S
N
NHR 1
N
R
2
CH
 
 R1= Ph ;   R2 = 2- OH Ph  showed the highest activity. 
 
Dilmaghani  et al., synthesized a series of new Schiff bases by the 
condensation reaction of 5-(4-aminophenyl)-N-aryl-1,3,4-thiadiazol-2-yl 
amines with salicylaldehyde, 3-hydroxy benzaldehyde, 4-hydroxy 
benzaldehyde, 5-bromo salicylaldehyde, 5-chloro salicylaldehyde, 4-
methoxy benzaldehyde, 3-nitro benzaldehyde, and 4-nitro benzaldehyde. 
The synthesized compounds were tested for their antimicrobial efficiency 
against Mycobacterium smegmatis PTCC 1307 in vitro. [46] 
N
S
N
NHR
1
N
R
2
CH
 
R1 = 4- BrC6H4   ;   R2 = 2- HOC6H4  showed highest antiproliferative activity 
against M. smegmatis. 
As antimicrobial agents 
Alok et al., synthesized Schiff bases of 2-amino-5-aryl-1,3,4-
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thiadiazole derivatives with different aromatic aldehyde and the 
compounds were evaluated for antibacterial activity.[47] 
R
N
N
S
N
R
1
 
The compounds showed significant antibacterial activity against 
Staphylococcus aureus (gram-positive bacteria) and E. coli (gram-negative 
bacteria). 
Abdalla M. Khedr  et al.,  reported the synthesis of  new mono- 
and binuclear copper(II) complexes with Schiff bases derived from the 
condensation of 2-amino-5-substituted-aryl-1,3,4-thiadiazole with 
substituted aryl aldehydes . 
The synthesized complexes and ligands were screened in-vitro for 
their antimicrobial activity against gram-positive bacteria (Staphylococcus 
aureus), gram-negative bacteria (Escherichia coli) and fungi (Aspergillus 
flavus and Candida albicans).[48] 
N
S
N
N
R1
R2 
R1=H, 4-Cl,  2-NO2, 4-OH, 4-N(CH3)2, 2-OH 
R2=4-NO2 , C6H5N , 2-Cl ,4-OCH3 , C 6H5N ,2-OH. 
R=OH R’=OH 
R=NO2 R’=OH 
R=OCH3 R’=OH 
R= N(CH3)2 R’= NO2 
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CHEMISTRY 
INTRODUCTION[49] 
Chromones (4H- Benzopyran- 4-ones) are the heterocyclic 
compounds containing  benzopyron network with substituted keto group 
on pyron ring. It is an isomer of coumarin.  
            3-Formylchromone (4-oxo-4H-chromene-3-carbaldehyde), is a 
fairly versatile molecule that is easily synthesized and frequently used for 
the incorporation of chromone moiety into other aromatic/heterocyclic 
molecules, or to construct new scaffolds based on this molecule. 
3-Formylchromones occupy a unique position due to three reasons:  
i) They are carrying significant biological activities like anticancer, 
antimicrobial, antioxidant, anti H.pylori activity, urease inhibitory 
activity.  
ii) They have comfortable preparation by Vilsmeier-Haack reaction in 
 very  good yields. 
 iii)   They are attractive intermediates. 
            Much of the synthetic utility of 3-formyl chromones is due to the 
presence of three electron deficient centers, the carbonyl carbon atoms  
C-4 and C-3' of the keto of  formyl groups respectively, and carbon atom 
C-2 of the chromone ring. Formyl chromones have been of synthetic and 
biological interest because of their synthetic utility based on the three 
electrophilic carbon atoms and the biological activities associated with the 
formyl chromone derivatives or structurally modified compounds. 
                
O
O
1
2
3
45
6
7
8                                             
O
O
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1
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6
7
8  
        4H- Benzopyran- 4-ones                      4-oxo-4H-chromene-3-carbaldehyde 
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GENERAL METHODS OF SYNTHESIS OF 3-FORMYL 
CHROMONE[50,51] 
I) Vilsmeier Haack Reaction. 
 The reaction of acetophenone with substituted amide, typically with 
N,N dimethyl formamide (DMF) and phosphorous oxy chloride 
(POCl3) leads to the formation of  3 -formyl chromones. 
CH3
OH
O
DMF
POCl3 O
O
CHO
 
 Acetophenone                                                3- formyl chromone 
MECHANISM 
N
CH3
CH3 H
O
+ P
O
ClCl
Cl
phosphoric trichloride
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+
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CH3 H
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O
Cl
Cl
Cl
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N
+
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CH3 H
Cl
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-
O
Cl
Cl
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+
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-
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N
+ CH3CH3
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O
-(CH3)2NH
N
+ CH3CH3
O
O
Hydrolysis
aq, CH3COONa
O
O
CHO
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 The active reagent is substituted chloro iminium ion that is formed 
by the reaction of DMF and POCl3. This chloro iminium ion then attacks 
the electron rich arene to give the corresponding aromatic ketone or 
aldehyde. 
II) One method for synthesis of 3 formyl chromone involves the 
preparation of appropriately substituted phenol derivatives  followed 
by Friedel-Crafts acylation to obtain 2-acetylphenol derivatives. 
Alternatively, 2-acetylphenol derivatives could be obtained by 
acetylation prior to the introduction of the substituent R. The core 
structure was then formed by Vilsmeier-Haack reaction in which 2-
acetyl phenol moiety in 2-acetylphenol derivative was converted to 
3-formylchromone structure in the presence of POCl3 and DMF. 
 
X
OH
Suzuki coupling 
or other reactions
R
OH
R
O
CH3O
R
OH
H
O
X
OH
CH3
O
X
O
CH3O
Vilsmeier Haack rn
CH3
O
O
CHO
REACTIONS OF 3- FORMYL CHROMONE[52- 57] 
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3- formyl chromone possesses an endocyclic olefinic bond, an α,β-
unsaturated carbonyl functionality, three electrophilic centres (C-2, 
aldehydic and ketonic carbons). These unique features make the 
chromone amenable to various reactions. 
1. Nucleophilic Addition 
              3-Formylchromone is a good Michael acceptor towards most, if 
not all, nucleophiles. Thus, a nucleophile XH2 such as an amine, 
hydrazine, monosubstituted hydrazine, hydroxylamine or an active methyl 
or methylene compound in conjugation with an appropriate base 
undergoes Michael addition with concomitant opening of the pyran ring 
and subsequent recyclization. (i.e. domino Michael–retro-Michael–
Intramolecular 1,2-addition) giving the hemiacetal that leads to final 
compound by water elimination.  
O
CHO
O
+ XH2
O
XHO
OH
-H2O
O
O X  
 
a) Addition of  sulfur nucleophiles 
3-Formylchromone when heated  with 2-phenyl-4-dimethylamino-1-thia-3-
azabutadiene in a sealed tube  gives1,2,4-dithiazole. 
O
O
CHO
+ N
S
Ph NMe 2
N
S S
Chr Ph
 
 
MECHANISM 
The first step involves thionation of 3- formyl chromone to thioformyl 
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chromone through  the [4+2] cycloadduct of 3- formyl chromone and 
thiazadiene. 
The second step involves the reaction of 3- thioformyl chromone 
with a molecule of thiobenzamide followed by oxidative cyclisation.  
O
O
CHO
+ N
S
Ph NMe 2
N
S
O
Chr CH3
NMe 2
PhCN
DMF
Chr
H
S
Ph
NH2
S
Chr
NH
SH
Ph
S
oxidative
cyclization
N
S S
PhChr
 
b) Addition of nitrogen nucleophiles 
i) Addition of aliphatic amines. 
Schiff bases are  obtained when  ChrCHO  is treated with  an 
aliphatic or aromatic amine RNH2. 
O
O
CHO
+ CH3
Si(OEt)3
O
O N
(CH2)3
Si(OEt)3
 
iii) Reaction with guanidine. 
Reaction of 3-formyl chromone with cyano guanidine or metformine 
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gives biologically important pyrimidine . 
O
O
CHO
N
NH2
NH2 CN
N
NH2
NH2 NH
Me2N
O
NN
X
OH
 
 X= NHCN, NHC(=NH)NMe2 
c)  Addition of carbon nucleophiles 
i)  Addition of active methyl and acyclic methylene compounds. 
The aryl (or hetaryl) methyl ketone condenses with 3-
formylchromone under various conditions to give the chalcones. 
O
O
CHO
+ MeCOR
O
O
RO
 
R= Aryl, hetaryl 
2) Baylis-Hillman reaction 
Synthesis of 3-hydrazino chromone from 3 formyl chromone and 
azidodicarboxylate (E = CO2Et or CO2Me) in the presence of DABCO 
(here written as NR3) involves an aza-Baylis-Hillman type reaction followed 
by deformylation. 
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O
N
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O
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4) 3-Formylchromone as a Component in One Pot Multi 
 component  Synthesis 
            Here 3-formylchromone with at least two other different reactants, 
if not more, put together at a time in one reaction vessel. As ChrCHO 
contains three electropositive centres, most of the other reacting partners 
should function as nucleophiles either in the absence or in the presence of 
a suitable catalyst.  
Biginelli Reaction 
ChrCHO when subjected to Biginelli reaction with a β-ketoester and 
guanidine or urea or thiourea behaves as a simple aldehyde to give the 
1,4-dihydropyrimidine derivative . 
O
O
CHO
+ R
CH2
O
R'OOC
NH2
NH2
X
O
N
H
NH
X
R
R'OOC
O
 
R = Me, R1 = Et; X = O,S,NH 
5) Three component reactions of 3-formylchromone with reagents 
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 other  than a nitrogen Nucleophile. 
Palladium catalyzed three component coupling reaction between 3 
formylchromone, alcohol and allyl acetate leads to the highly substituted 
chromanone. 
O
O
CHO
+ ROH + CH2
OAc
Pd(PPh3)4 (10 mol%)
THF,rt
O OR
O
CHO
CH2
 
6) 3-Formylchromone as a component in the four component 
 reactions 
Hantzsch synthesis 
Application of the Hantzsch procedure for synthesis of 1,4-
dihydropyridine in one-pot reaction of ChrCHO, dimedone, ethyl 
acetoacetate and ammonium acetate gives the cyclohexanopyridine 
derivative. 
O
O
CHO
+
O O
CH3 CH3
+ CH3 O CH3
O O
+ CH3
ONH4
O
N
H
COOEt
ChrO
CH3
CH3
CH3
 
 
7. Reaction of 3- formyl chromone to yield Pyrimido[1,2-
 a]pyrimidines . 
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Pyrimido[1,2-a]pyrimidines were prepared from dihydro amino 
pyrimidines and chromone-3- aldehydes . Reactions are much faster and 
better yields have been obtained with microwaves. 
N
N
H
Ar H
EtOOC
Ph NH2
+ O
O
O H
N
N N
O
OH
EtOOC
Ph
Ar H
N
N N
O
OHAr
EtOOC
Ph
H  
Ar= C6H5,4- CH3C6H4, 4-ClC6H4 
 
8. Reaction of 3- formyl chromone to yield  1,3,4- oxadiazol- 2 
chromone The treatment of the 3-formylchromones with aroylhydrazines 
give the corresponding aroylhydrazones which in the presence of acetic 
anhydride undergoes  heterocyclization to afford 3-(3-acetyl-5-aryl-2,3-
dihydro-1,3,4-oxadiazol-2-yl) chromones . 
O
CHO
R
1
R
2
ArCONHNH2
O
N
NHCOAr
R
1
R
2
O
Reflux
(MeCO)2O
O
N
O
N
O
R
1
R
2
COCH3
Ar  
 
Michael–Retro-Michael–Aldol Reaction 
The reaction of 3-formylchromones with Me 3SiOTf  and 1,3-bis(silyl 
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enol ether)afforded the 4-(2-hydroxybenzoyl)phenols . The formation of the 
products could be explained by a domino ‘‘Michael–retro-Michael–Aldol’’ 
reaction. 
O
O
CHOR
1
+ (CH3)3SiOTf +
(H3C)3SiO
O OSi(CH3)3
CH3
O
CHO
OSi(CH3)3
H
O
R
1
OSi(CH3)3
O
OH
R
1
O O
 
R1= H, alkyl, aryl 
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2- AMINO 5 -ARYL 1,3,4 THIADIAZOLES[58-60] 
INTRODUCTION  
Thiadiazole is a 5-membered ring system containing hydrogen-
binding domain, sulphur atom, and two-electron donor nitrogen system  
(–N=C–S) that exhibit a wide variety of biological activity. They occur in 
four isomeric forms in the nature viz. 1,2,3-thiadiazole ; 1,2,5-thiadiazole ; 
1,2,4-thiadiazole ; and 1,3,4- thiadiazole .  
N
N
S
1,2,3- thiadiazole
N
S
N
1,2,5- thiadiazole
N
S
N
1,2,4- thiadiazole
S
N N
1,3,4- thiadiazole
 
                                       Four Isomeric Forms of Thiadiazole  
Among these four types of thiadiazole, 1, 3, 4- thiadiazole is well 
known.  
1,3,4-Thiadiazoles were conveniently divided into three subclasses:  
a)  Aromatic systems which include the neutral thiadiazole (4).  
b)  Mesoionic systems (4a) which is defined as five-membered 
heterocycles which are not covalent or polar and possess a sextet 
of electrons in association with the five atoms comprising the ring.  
c) Non aromatic systems such as the 1,3,4-thiadiazolines (4b, 4c) and 
the tetrahydo 1,3,4-thiadiazolidines (4d). 
S
N N
S
N
+
N
R
X S
N N
H
S
N N
S
N
H
N
H
(4a) (4b) (4d)(4) (4c)  
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Literature survey revealed that various thiadiazoles posses 
pharmacological activities including antitumor , antiviral, antibacterial, 
amoebicidal, antiinflammatory, antitubercular, antipyretic,CNS depressant,  
herbicidal , insecticidal, pesticidal and  hypoglycemic. 
GENERAL METHODS OF SYNTHESIS OF 2 AMINO 5 ARYL  1,3,4 
THIADIAZOLE 
1) From Thiosemicarbazides and carboxylic acid derivatives: 
i) Reaction of thiosemicarbazide with carbon source reagents in the 
presence of dehydrating agents provides a useful route to 1,3,4-
thiadiazoles . The reaction proceeds via the monothiodiacyl hydrazines. 
Carbon source may be aliphatic, aromatic, heterocyclic carboxylic acids, 
esters or acid chlorides and the dehydrating agents are phosphorus 
oxychloride , sulfuric acid , and PPA  
NH2
NH NH2
S + R
1
COOH R
1
O
NH NH
NH2
S
S
N N
R
1
NH2
 
R1= phenyl, isopropyl, benzofur-2-yl, methyl 
2)  From thioacylhydrazone 
Oxidative cyclization of thioacylhydrazone by common oxidants 
such as bromine , ferric chloride , ammonium ferric sulfate  or potassium 
permanganate provided 2-amino-5-phenyl-1,3,4-thiadiazole . 
N NH
Ph
H
NH2
S
oxidative cyclization
S
N N
NH2Ph
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3) From hydrazonoyl thiocyanate 
When hydrazonoyl thiocyanates were heated in toluene, they were 
converted into the thiadiazole derivatives, but on acid hydrolysis in 
refluxing ethanol it will give aldehyde and the aminothiadiazole derivatives. 
N
NCS
NAr
Ar
,H+
ethanol
S
N N
NH2Ar
+ Ar'CHO
 
4) From benzothiazines 
4H-3,1-Benzothiazine-4-thione was treated with S-methyl 
isothiosemicarbazide hydroioide in ethanol containing sodium acetate to 
yield the 5-aryl-2-amino-1,3,4-thiadiazole . A suitable mechanism for this 
transformation requires the addition of one of the amino groups from the 
thiosemicarbazide to the thiocabonyl group of the benzothiazin-4-thione 
followed by ring opening and recyclization with elimination of CH3SH to 
give the thiadiazole . 
S
N Ph
S
+
NH2 N
SMe
NH2
.HI
EtOH
AcONa
S
N N
NH2
NH
Ph
S
 
5)   From thiosemicarbazide and aldehydes 
2-amino-5-aryl-1,3,4-thiadiazole can be  prepared by the reaction of 
thiosemicarbazide, sodium acetate and aromatic aldehyde. 
R
CHO
+ NH2 NH
NH2
S
R
N
NH NH2
S
CH3COONa
Br2,CH3COOH
CH3COONa
N
S
N
NH2
R  
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REACTIONS OF 2- AMINO 5- ARYL  1,3,4 THIADIAZOLE 
I. Reactivity of 1,3,4-thiadiazole ring 
1. Electrophilic attack at nitrogen 
The ring nitrogens react with electrophiles to afford either 1,3,4- 
thiadiazolium salts or 1,3,4-thiadiazol-2(3H)-ones. While N-alkylation is the 
most common electrophilic reaction of 1,3,4-thiadiazole, reactions with 
acyl and cyanogen halides as well as Mannich salts have also been 
reported. 2-Amino-1,3,4-thiadiazole reacts with chloroacetone to give the 
N- alkylated thiadiazolimine. 
S
N N
R NH2 ClCH2Ac
CH3CN, reflux, 8 hrs
S
N N
R
Ac
NHHCl
 
2. Nucleophilic attack at carbon 
Nucleophilic reactions at the carbon atoms of 1,3,4-thiadiazoles 
occur readily owing to the electron-deficient nature of the ring.  
2-Amino-1,3,4-thiadiazoles undergo Sandmeyer reactions to afford 
2-halo-1,3,4-thiadiazoles. Diazotization followed by a Sandmeyer reaction 
of the 2-amino-5-phenyl-1,3,4-thiadiazole with CuCl generated in situ will 
give 2-chloro-5-phenyl-l,3,4-thiadiazole. 
S
N N
NH2Ph
S
N N
ClPhamyl nitrite
CuCl/CH3CN
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II) Reactivity of substituents attached to ring carbon atoms 
 Nitrogen substituents: 
 Treatment of 2-amino-5-substituted thiadiazoles with ethyl 
cyanoacetate in the presence of sodium methoxide gave the 2-
substituted- 5- imino-6H-[1,3,4-thiadiazolo[3,2-a]pyrimidine-7-one 
which on further treatment with DMF/POCl3 yielded the 5-
isocyanide derivative . 
S
N N
NH2R NaOMe
MeOH
N
N
H
N
S
NH
O
R
N
N
NC
N
SO
R
POCl3
DMF
 
 Treatment of 2-amino-5-substituted thiadiazoles with ethyl 
cyanoacetate in the presence  of P2O5 and CH3SO3H , 7-
amino[1,3,4]-thiadiazolo[3,2-a]pyrimidine-5-one was obtained. 
S
N N
NH2R
+ NC
O
EtO
P2O5
MeSO3H
N
N
N
S
O
NH2
R
 
 Reaction of 2-amino-5-aryl-thiadiazole with aryl nitriles in the 
presence of aluminum chloride produced the aryl amidine which 
was oxidized with lead tetraacetate to yield 2,6-diaryl-[1,2,4]-
triazolo[5,1-b]- 1,3,4-thiadiazoles . The yields of amidines depend 
on the reactivity of the nitriles. Decreasing the electron density of 
the cyano group by such electron-withdrawing groups as p-
nitrophenyl, and 2 and 4-cyanopyridyl led to higher yields as 
compared to unsubstituted benzonitrile. 
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S
N N
R NH2 ArCN
AlCl3
S
N N
R
Ar
NH2
CH3
R=Ar'
Pb(OAc)4
S
N N
N
N
Ar
Ar
 
 A bis thiadiazole can be prepared by reacting the sodium salt of  2-
amino-5-aryl-thiadiazole with 2-methane sulfonyl-5-t-butyl-1,3,4-
thiadiazole. 
S
N N
R NH2
+
S
N N
R SO2Me
S
N N
NH
S
N
N
R
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCHIFF’S BASE[61, 62] 
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INTRODUCTION 
N
R1
R2 R3 
R1, R2= alkyl,aryl or H 
R3= alkyl ,aryl 
General structure of a Schiff base 
Schiff bases are biologically as well as synthetically important 
nitrogen containing compounds having azomethine group (-CH=N-) and 
are formed by condensation between primary amines and carbonyl 
compounds.Schiff bases exhibits a broad range of biological activities 
including antifungal, antibacterial, antimalarial, antiproliferative, anti-
inflammatory, antiviral,anti-tubercular and antipyretic properties  
Schiff bases have a large number of synthetic uses in organic 
chemistry. Acylation of Schiff bases by acid anhydrides, acid chlorides and 
acyl cyanides is initiated by attack at the nitrogen atom and leads to net 
addition of the acylating agent to the carbon-nitrogen double bond. 
Reactions of this type have been put to good use in natural product 
synthesis.  
            Schiff bases appear to be an important intermediate in a number of 
enzymatic reactions involving interaction of an enzyme with an amino or a 
carbonyl group of the substrate. One of the most important types of 
catalytic mechanism is the biochemical process which involves the 
condensation of a primary amine in an enzyme usually that of a lysine 
residue, with a carbonyl group of the substrate to form an imine, or Schiff 
base. 
 
GENERAL METHODS FOR THE FORMATION OF C=N BONDS 
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a)  Amine carbonyl condensations: 
 The classic method for the introduction of the carbon nitrogen 
double bond into the molecule involves the condensation of aldehydes and 
ketones with a variety of amino compounds ( amines, hydroxylamines, 
hydrazines) followed by elimination of elements of water to give 
corresponding azomethines. 
O
R1
R2
+ R3 NH2 N
R1
R2 OH R3
H
N
R1
R2 R3
+ H2O
R1,R2= H, alkyl,aryl 
R3= alkyl, aryl, OH,OR,NHR 
b) Condensation reaction involving active methylene compounds: 
 Aromatic nitroso compounds undergo base catalysed condensation 
with active methylene compounds to give intermediate adducts 
(hydroxylamine derivatives ) which can be dehydrated to azomethines. 
N O
Ar
+ R2
R1
base -H2O
N
Ar
R2
R1
R2
R1
N
Ar
OH  
c )  Dehydrogenation (oxidation) of amino compounds to 
 azomethines: 
 The dehydrogenation of primary or secondary alkyl amines over 
nickel, platinum, chromium catalysts or in contact with sulphur, or selenium 
gives acceptable yields of corresponding azomethines. 
Reagent used: Hydride transfer reagents (diazonium fluoroborates, 
trityl perchlorate) 
N
R4
R3R1
R2
N
+
R4
R3R1
R2  
d) Elimination reaction leading to azomethines: 
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 Thermal and base catalysed elimination of substrates derived by 
electroplilic attack (halogenations, nitrosation, nitration, sulphonation) at 
the nitrogen atom of primary and secondary alkylamines. 
X
R3R2
R1 H
base or heat
-HX
N
R3
R1
R2
 
GENERAL REACTIONS OF SCHIFF BASES 
a)  Reaction with electrophiles  
 Electropliles attack predominantly at nitrogen atom in the 
azomethines. 
i) Halogenation 
 Halogens are reported to add in a 1,2-fashion to the carbon-
nitrogen double bond in N-arylaldimines. The product of the reaction of 
benzylidene aniline with bromine in carbon tetrachloride is formulated as 
an N-bromoiminium bromide. 
Ph
N Ph + Br2 Ph
N
+
Ph
Br
Br
-
+
 
ii) Alkylation 
 Direct alkylation of N-alkyl aldimines and ketimines occurs at the 
nitrogen atom to give corresponding iminimum salt. N-alkylation of N-
monosubstituted hydrazones has been applied intramolecularly providing 
a general route to pyrazolines. 
R1
R2
X
N
R3
NH
R4
N
N
R4
R2
R1 R3
- HX
 
iii) Acylation: 
Chemistry 
 
 
 
Department of Pharmaceutical Chemistry 50 
 Acylation of Schiff’s base by acid anhydrides, acid chlorides and 
acyl cyanides is initated by attack at the nitrogen atom and leads to net 
addition of acylating agent to the carbon nitrogen double bond. 
N
H
ArPh
+ CH3
O
CHCl 2 Et3N
N
+
Ar
H Ph
CCl2
O
-
N
ClCl
O
Ar
Ph  
 
b)  Reaction with nucleophiles 
 Nucleophilic reagents attack azomethines at imidyl carbon atom. 
1) Alkoxide adds to Schiff’s base giving corresponding α- alkoxyamino 
 compounds. 
 
N
O
R
R
NOC2HCOPh
MeOH
N
PhOCHC2ON
MeO
O R
R
 
 
2) Reaction with Grignard reagents: Schiff base lacking hydrogen 
atoms α to the carbon nitrogen double bond react with Grignard 
reagents to give adducts which on hydrolytic workup afford 
secondary amine in excellent yield. 
N
CH3
R1
R2
R
4
MgX
N
XMg
R3R4
R2 R1
NH
R3
R4
R2 R1
 
 
 
3) Reaction with active methylene compounds: Schiff base react 
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readily with active methylene compounds to give adducts which 
tend to eliminate the elements of an amine affording the 
corresponding alkene. 
N
H
ArR
+ X
Z
X
Z Ar
NH R
-RNH2 Z
XAr
H
 
c)  Oxidation  
 Oxidation of Schiff base with a peroxy acid results in cleavage of 
carbon nitrogen bond to give a carbonyl compound and a nitroso 
compound. On the other hand oxidation using peroxy acid at low 
temperature (0 0 C) affords an excellent synthetic route to oxaziridines. 
N
R3
R1
R2
R
4
COOH O
N
R3R1
R2  
d) Reduction  
 Alkali metals in inert solvents such as ether or toluene tend to 
promote reductive dimerization by a radical coupling mechanism to afford 
diamino compound as a major product. Metal proton reagents (sodium, 
sodium amalgam, magnesium, aluminium in ethanol etc.) smoothly reduce 
Schiff base to corresponding amines. 
R1
N
Ar
R2
Ph
N
-
Ar
-
R1 Ph
R2
NH
Ar
R1 R2
Ph
NH
Ph
R2
Ar R1
NH
Ar
R1
Ph
R2
 
MECHANISM 
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 Imines are prepared by a reaction between a carbonyl compound 
and a primary amine. If the imine contains a hydrogen atom, it is unstable 
and usually cannot be isolated. However when the imine contains aromatic 
group on the nitrogen, the resulting imine is stable and can be isolated. 
The products are called Schiff  base.    
 
Step 1: 
O
R1
R2
+ NH2 R3 N
+
H
R3
H
R2
O
-
R1
N R1
OH
R2
H
R3
..
 
 Nucleophilic addition of the amine to the carbonyl compound 
followed by transfer of a proton from nitrogen to oxygen leads to the 
formation of tetrahedral carbinolamine intermediate. 
 
Step 2: 
 Elimination of water to gives the corresponding azomethines. 
N R1
OH
R2
H
R3
N
R3
R2
R1
+ OH2
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PURPOSE AND PLAN OF WORK 
Enzyme inhibitors are used as potent therapeutic agents for the 
treatment of various diseases. More than 100 drugs used worldwide are 
enzyme inhibitors. 
              Thymidine phosphorylase is a highly expressed protein in many 
solid human tumours. This has been identified as a potential target in the 
development of anti-cancer drugs. Abnormally the level of thymidine 
phosphorylase is highly expressed in various pathological disorders 
including pancreatic, gastric carcinoma, colon carcinoma, uterine sarcoma, 
renal carcinoma, breast and lung cancers, astrocytic tumors, cervical 
intraepithelial neoplasia, carcinomas of the ovary and bladder, Kaposi 
sarcoma, atherosclerosis, and in various inflammatory diseases. 
Identification of effective inhibitors of thymidine phosphorylase is, 
therefore, a need for the treatment of various types of neoplastic and non-
neoplastic diseases. 
Currently only one TP inhibitor (tipiracil), in combination of 
trifluridine (a cytotoxin), is recently approved by U.S. FDA for clinical use 
for the treatment of metastatic colorectal cancer. This combination drug 
(trifluridine/ tipiracil), marketed as Lonsurf, is also associated with severe 
side effects, such as myelosuppression, anemia, and neutropenia. 
Therefore there is need to develop new TP inhibitory agents. 
Indeed, a potent inhibitor of TP, 5-chloro-6-[(2-iminopyrrolidin-1-
yl)methyl]uracil (TPI)  entered phase II clinical trials in combination with 5-
trifluoromethyl- 2α-deoxyuridine as an orally available anticancer treatment 
under the name of TAS-102. 
3-Formylchromone is a fairly versatile molecule that is easily 
synthesized and its Schiff bases are associated with a wide range of 
biological activities including antimicrobial, anticancer, anti inflammatory, 
antioxidant activities. In addition literature review also revealed that Schiff 
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bases of 3 formyl chromone exhibit thymidine phosphorylase inhibitory 
activity. 
            Thiadiazole is also a potent nucleus which exhibits 
pharmacological activities such as antitumor, antiviral, antibacterial, 
amoebicidal, antiinflammatory, antitubercular, antipyretic, CNS depressant 
and  hypoglycemic activities. 
Based on the above facts, the present work is focused on synthesis 
of Schiff bases of 7- hydroxyl - 3 formyl chromone  using various 2- amino 
5 aryl 1,3, 4 thiadiazole as novel  thymidine phosphorylase inhibitors. 
 3- formyl chromone, 1,3,4 thiadiazole  and Schiff bases have been 
reported to possess antimicrobial properties. Hence the synthesized  
compounds are screened   for  their invitro antimicrobial activity  against 
selected strains of Gram positive and Gram negative bacteria and fungi. 
 The present work consists of the following different stages:- 
Phase I      :   Literature review 
Phase II     :   Synthesis of  various Schiff bases of 7- hydroxyl  3- formyl   
                        chromone. 
Phase III    :    Spectral studies of synthesized compounds 
Phase IV   :     Evaluation of invitro Thymidine phosphorylase inhibitory  
                       activity. 
Phase V    :    Antimicrobial screening of synthesized compound 
                        Antibacterial studies 
            Minimum Inhibitory Concentration 
                        Antifungal studies 
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EXPERIMENTAL WORK 
 
a. MATERIALS AND METHODS 
            Chemicals used 
2,4–dihydroxyacetophenone, dimethyl formamide,phosphorous oxy 
chloride,thiosemicarbazide, conc. sulphuric acid,2- chloro benzoic acid, 3- 
chloro benzoic acid, 4- chloro benzoic acid, 2,4- dichloro benzoic acid, 2- 
nitro benzoic acid, 3- nitro benzoic acid, 4- nitro benzoic acid, 3,5- dinitro 
benzoic acid, methanol. 
Apparatus used 
Beakers, test tubes, conical flask, round bottom flasks, reflux 
condenser, thermometer, glass rods, funnel, mechanical stirrer. 
Analytical works 
 Melting points were determined using melting point apparatus LAB 
 INDIA  MR- VIS Scientific. 
 Reactions were monitored by the thin layer chromatography (TLC) 
on precoated silica gel G plates using iodine vapour as visualizing 
agent. 
 IR spectra were recorded on JASCO FT/IR -140 spectrophotometer  
in the Department of Pharmaceutical Analysis, College of 
Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, 
Coimbatore. 
 UV spectra were recorded on JASCO V-530 UV/VIS 
spectrophotometer in the Department of Pharmaceutical analysis, 
College of Pharmacy, Sri Ramakrishna Institute of Paramedical 
Sciences, Coimbatore. 
 PMR spectra were recorded using BRUKER AV III FT-NMR 500 
 MHz  in the SAIF, IIT Madras. 
 Mass spectra were recorded using JEOL GC Mate GC-MS 
 spectrometer  in the SAIF, IIT Madras. 
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SCHEME 
Method 
Step 1:Synthesis of 7 hydroxy 3 formyl chromen-4-one[31] 
In dry DMF (60 ml) in three neck flask, POCl3 (37.5 ml) was added 
slowly with vigorous stirring at 50oC. Heating and stirring was continued for 
2 hrs at 45-55°C. The solution of resacetophenone (9.12 gm) in DMF (12.5 
ml) was then slowly added with stirring at 50oC and stirring was continued 
for 2 hrs. After cooling the mixture was kept overnight at room temperature 
and diluted slowly by adding ice cold water (250 ml) and was stirred again 
for 6hrs. The red crystalline product separated was filtered and 
recrystallised from methanol. 
Step 2:  Synthesis of 2-amino-5-aryl-1,3,4- thiadiazole[63] 
Thiosemicarbazide (0.01 mole), aryl carboxylic acid (0.01 mole) and conc. 
sulphuric acid (5 ml) were refluxed for 2 hours. The reflux was continued 
for further time of span until we get a distinct single point on TLC. This hot 
mixture was poured on to crushed ice. The solid separated was filtered out 
and washed with water. It was recrystallized from methanol. 
Step 3:Synthesis of Schiff bases[31] 
           Schiff bases were prepared by reaction of equimoles of 7-hydroxy-
3-formyl chromen-4-one and various amines. 7-Hydroxy-3-formyl 
chromen- 4-one (0.01 mole) was dissolved in 5 ml methanol. Amine (0.01 
mole) was added with constant stirring. To the resulting mixture 2-4 drops 
of concentrated H2SO4 was added and the mixture was refluxed for 1-2 
hrs. After completion of reaction, mixture was poured over crushed ice with 
stirring. The product obtained was filtered and recrystallised from 
methanol. 
SCHEME 
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Step 1 
OH
CH3
O
OH
DMF, POCl3
45-550 C
O
CHO
O
OH
2,4 - dihydroxy acetophenone 7 -hydroxy 3- formyl chromone 
Step II 
NH
NH2
SNH2
+
COOH
R
conc. H2SO4
2 hrs reflux
N
S
N
NH2
R
Thiosemicarbazide Substituted
aromatic acid
2 - amino 5 - aryl
1,3,4 - thiadiazole  
Step III 
O
CHO
O
OH
N
S
N
NH2
R+
O
O
OH
N S
N N
R
conc H2SO4
1-2 hrs reflux
7 - hydroxy 3 - formyl chromone 2 - amino 5 - aryl
1,3,4 - thiadiazole
Schiff base  
 
Schiff Base 
Compound 
code 
R 
Ia 2-Cl 
Ib 3-Cl 
Ic 4-Cl 
Id 2,4-Cl 
Ie 2- NO2 
If 3- NO2 
Ig 4- NO2 
Ih 3,5- NO2 
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Table No:1 PHYSICAL CHARACTERISATION OF NEWLY SYNTHESIZED COMPOUNDS 
O
O
OH
N S
N N
R  
Compound 
code 
R Molecular formula 
Molecular 
weight 
Melting point 
°C 
Rf value % yield 
Ia 2-Cl C18H10ClN3O3S 383.80 138.6 0.3617 77% 
Ib 3-Cl C18H10ClN3O3S 383.80 145.4 0.3409 74% 
Ic 4-Cl C18H10ClN3O3S 383.80 143.5 0.7272 77% 
Id 2,4-Cl C18H9Cl2N3O3S 418.25 165.8 0.906 84% 
Ie 2- NO2 C18H10N4O5S 394.36 123.4 0.40 83% 
If 3- NO2 C18H10N4O5S 394.36 100.6 0.6190 78% 
Ig 4- NO2 C18H10N4O5S 394.36 216.7 0.5714 86% 
Ih 3,5- NO2 C18H9N5O7S 439.35 168.5 0.7431 85% 
Recrystallisation solvent :  Methanol 
Solvent system for TLC    :  Chloroform:DMSO(9:1) 
Visualizing agent :  Iodine vapour 
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SPECTRAL CHARACTERIZATION DATA[64-66] 
The structures of synthesized compounds during the present 
investigation were established on the basis of chemical data, IR,UV, NMR 
and Mass spectral data. The purity of compounds were established by 
single spot on TLC plates. 
Compound code: Ia 
O
O
OH
N S
N N
Cl
 
 
Chemical name 
 3-[(E)-{[5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 540 nm 
IR ( KBr,νmax in cm-1) 
3434.6 (Aromatic O-H) 
1633.41 (C=O) 
1506.13(C=N) 
1132.97 (cyclic ester C-O-C) 
 743.42 (C-S) 
 1021.12(N-N) 
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UV SPECTRUM 
 
IR SPECTRUM 
 
 
Compound code : Ib 
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O
O
OH
N S
N N
Cl
 
 
Chemical name 
 3-[(E)-{[5-(3-chlorophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 536 nm 
 
IR ( KBr,νmax in cm-1) 
3428.81 (Aromatic O-H) 
1633.41 (C=O) 
1533.13(C=N) 
1139.72 (cyclic ester C-O-C) 
 666.285 (C-S- C linkage) 
 1021.12(N-N) 
1H NMR spectral data 
 13.226  (s, 1H, Ar- OH) 
 7.526- 7.905  (m, 7H, Ar- H & 1H, CH=C) 
  
 
 
Mass Spectral Data 
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Molecular weight of compoundIb :  383 
Sl NO Fragment m/z value 
 
1. 
 
O
O
OH
N S
N N
Cl
M
+
 
383 
 
2. 
 
 
 
O
O N S
N N
Cl
 
319 
3. 
 
 
 
 
 
 
O
N S
N N
Cl
 
305 
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Compound code : Ic 
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Chemical name 
3-[(E)-{[5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 542 nm 
IR ( KBr,νmax in cm-1) 
3431.71 (Aromatic O-H) 
1629.55 (C=O) 
1585.2(C=N) 
1107.9 (cyclic ester C-O-C) 
768.49 (C-S) 
1021.12(N-N) 
1H NMR spectral data 
7.511-7.999 (m, 6H,Ar-H & 1 H, CH=C ) 
8.784 (s, 1H,CH=N) 
10.115 (s, 1H,Ar –OH) 
 
 
 
 
Mass Spectral Data 
Molecular weight of compound Ic : 383 
O
O
OH
N S
N N
Cl
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Sl No. Fragments m/z 
1. 
O
O
OH
N S
N N
Cl
M
+
 
383 
2. 
 
CH2 O
O N S
N N
CH3
 
247 
3 
O
O  
146 
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1H NMR SPECTRUM 
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Compound code: Id 
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Chemical name 
 3-[(E)-{[5-(2,4 -dichlorophenyl)-1,3,4-thiadiazol-
2-yl]  imino}methyl]  -7-hydroxy-4H- chromen-4-
one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 535 nm 
 
 
 
IR ( KBr,νmax in cm-1) 
3436.53 (Aromatic O-H) 
1634.38 (C=O) 
1531.2(C=N) 
1127.19 (cyclic ester C-O-C) 
 762.70 (C-S) 
 1019.19(N-N) 
 
 
 
 
 
 
 
UV SPECTRUM 
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Compound code : Ie 
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Chemical name 
3-[(E)-{[5-(2- nitrophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 534 nm 
IR ( KBr,νmax in cm-1) 
3432.67 (Aromatic O-H) 
1632.45 (C=O) 
1532.17(C=N) 
640.25 (C-S-C linkage) 
1021.12(N-N) 
 
 
 
 
 
 
 
 
UV SPECTRUM
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Chemical name 
3-[(E)-{[5-(3- nitrophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 538 nm 
IR ( KBr,νmax in cm-1) 
3433.64 (Aromatic O-H) 
1626.66 (C=O) 
1531.2(C=N) 
1134.9 (cyclic ester C-O-C) 
652.786 (C-S) 
1021.12(N-N) 
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Chemical name 
 3-[(E)-{[5-(4-nitrophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
UV spectrum 
Solvent used  :  DMSO 
λ max : 536 nm 
IR ( KBr,νmax in cm-1) 
3437.49 (Aromatic O-H) 
1629.55 (C=O) 
1540.85(C=N) 
1106.94 (cyclic ester C-O-C) 
 715.46 (C-S- C linkage) 
 1017.27(N-N) 
 
1H NMR spectral data 
7.841-8.001 (m, 6H,Ar-H & 1 H, CH=C) 
8.784 (s, 1H,CH=N) 
10.115 (s, 1H,Ar –OH) 
 
 
 
 
 
MASS SPECTRAL DATA 
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Molecular weight of compound Ig : 394 
Sl No. Fragments m/z 
1. 
O
O
OH
N S
N N
NO2
M
+
 
 
394 
2. 
O
CH3
N S
N N
CH3
CH3
 
325 
3. 
CH2
CH2
O
O N SH
NH  
210 
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Compound code : Ih 
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Chemical name   3-[(E)-{[5-(2,5-dinitrophenyl)-1,3,4-thiadiazol-2-yl]  
imino}methyl]  -7-hydroxy-4H- chromen-4-one 
 
UV spectrum Solvent used  :  DMSO 
λ max : 535 nm 
 
IR ( KBr,νmax in cm-1) 
3429.78 (Aromatic O-H) 
1628.59 (C=O) 
1544.7(C=N) 
1096.33 (cyclic ester C-O-C) 
 695.212 (C-S- C linkage) 
 1021.12(N-N) 
 
1H NMR spectral data 
7.511-7.999 (m, 6H,Ar-H & 1 H, CH=C) 
 8.784 (s, 1H,CH=N 
10.115 (s, 1H,Ar –OH) 
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Molecular weight of compound Ih : 439 
Sl No. Fragments m/z 
1. 
O
O
OH
N S
N N
O2N NO2
M
+
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ENZYME INHIBITORY STUDIES[67-69] 
In vitroThymidine  Phosphorylase Inhibitory Activity 
Principle: 
Thymidine  +  Orthophosphate  
TP
 Thymine  + 2- Deoxy – D- 
                                                                             Ribose Phosphate 
The rate of decrease in absorbance due to conversion of thymidine 
to thymine monitored at 290 nm is the rate of enzymatic activity. A 
comparison of the rate of  enzymatic reaction in the absence and presence 
of inhibitor or test compound would give the relative extent of enzyme 
inhibition. 
Conditions: T = 250 C, pH = 7.4, A290 nm, Light path = 1 cm. 
Method : Continuous Spectrophotometric rate determination.  
MATERIALS AND METHODS 
Chemicals Required 
Recombinant E.coli thymidine phosphorylase enzyme, potassium 
phosphate monobasic, anhydrous and Thymidine were obtained from 
Sigma. 
Inhibition of Thymidine phosphorylase by in vitro method 
REAGENTS: 
1. Reagent A (200 mM Potassium phosphate Buffer, pH 7.4 at   
 25° C) 
Reagent A was prepared by dissolving 13.61g potassium phosphate, 
monobasic, anhydrous in deionized water and diluted to 500 ml. 125 ml of 
above solution was transferred to 500 ml standard flask and added 39.1 ml 
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1M NaOH to adjust pH 7.4 at 250 C. Made up to final volume with deionized 
water. 
 
2.  Reagent B (5 mM Thymidine solution) 
Reagent B was prepared by dissolving 0.1211g Thymidine in  
100 ml Reagent A. 
 
3. Reagent C (10 mM potassium phosphate buffer, pH 7 at 25°C- 
 Enzyme Diluent) 
 Reagent C was prepared by dissolving 1.361g potassium 
phosphate,monobasic, anhydrous in deionized water and diluted to 1000 
ml. 25 ml of above solution was transferred to 100 ml standard flask and 
added 14.55 ml 1M NaOH to adjust pH 7.4 at 25° C. Made up to final 
volume with deionized water. 
 
4. Reagent D (Thymidine phosphorylase enzyme solution) 
Immediately before use, prepare a solution containing 1.5 units/ml 
of Thymidine Phosphorylase in cold Reagent C. 
PROCEDURE 
The enzymatic  assay was performed at room temperature in a  
JASCO V-530 UV/VIS spectrophotometer  using a detection wavelength of 
290 nm. 10 µl of TP solution (1.5 U/ml in pH 7.0 phosphate buffer),10 µl of 
the test compound solution in DMSO (for blank, 10 l DMSO was added) 
and 200 µl of thymidine solution (5mM in pH 7.4 phosphate buffer) were 
added to 780 µl of phosphate buffer (pH 7.4) in a 1.5 ml cuvette. After 
gentle shaking by inversion of the cuvette, the absorbance values at 4 min, 
8 min, 12 min, 16 min and 20 min were recorded successively. These 
absorbance values were plotted against time and linear regression was 
performed to obtain the slope of the line plotted which was taken to be the 
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velocity of enzyme catalyzed reaction. The percentage inhibition at this 
concentration was calculated by dividing the difference between the 
enzymatic velocity of the blank and the enzymatic velocity in the presence 
of the inhibitor (or test compound) by the enzymatic velocity of the blank. 
To determine the IC50 value of a certain compound, percentage inhibitions 
of at least 7 different concentrations that span over the estimated IC50 
values were determined by the method mentioned above and plotted 
against concentration using Graph Pad Instat software. The IC50 value was 
determined as the concentration of the inhibitor that caused 50% inhibition. 
Assay was done in triplicate and the results were expressed as standard 
error of mean.   
                                   % inhibition =
0
10
A 
A - A 
 
                       A0= Enzymatic  velocity of blank 
                       A1= Enzymatic velocity of test compounds 
DEFINITION OF UNIT 
One unit of TP will convert 1 µmole each of thymidine and 
phosphate to thymine and 2 α deoxy ribose 1 phosphate per minute at pH 
7.4 at 25°C. 
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Table 2 :In vitro  thymidine phosphorylase inhibitory activity of compounds Ia -Ih 
Compound 
code 
10 µg/ml 20 µg/ml 40 µg/ml 80 µg/ml 160 µg/ml 320 µg/ml 640 µg/ml IC50 µM 
Ia 
 
39.91±0.1933 42.63±0.1933 48.63±0.1933 60.07±0.1933 69.98±0.1933 74.80±0.1967 78.86±0.1933 63.63±3.6 
Ib 
 
38.75± 
0.1933 
43.79±0.1933 49.41±0.3378 56.03±0.1933 62.00±0.1933 68.98±0.1933 75.19±0.1933 154.97±4.1 
Ic 
 
41.39±0.0633 43.6±0.5800 50.18±0.0933 59.10±0.3867 71.11±0.0933 82.26±0.1933 88.56±0.1933 29.13±2.1 
Id 
 
40.30±0.1933 43.21±0.1933 49.60±0.1967 61.42±0.1933 68.21±0.1933 74.21±0.1933 79.45±0.1967 39.13±3.5 
Ie 
 
38.17±0.3867 44.37±0.1933 49.02±0.1933 62.59±0.1967 69.63±0.2267 72.67±0.3349 78.86±0.1933 41.08±3.2 
If 
 
38.75±0.1933 42.05±0.1933 47.47±0.1933 61.42±0.1933 68.40±0.1933 74.80±0.1967 76.54±0.1933 74.18±2.72 
Ig 
 
40.81±0.5233 43.21±0.1933 49.99±0.3378 60.07±0.3867 75.77±0.1933 85.85±0.1967 93.35±0.1233 23.36±1.16 
Ih 
 
35.84±0.1933 43.98±0.1933 48.25±0.3349 57.93±0.1933 67.63±0.1933 71.70±0.1933 74.02±0.1933 106.7±3.49 
7- 
Deazaxanthine 
(Standard) 
       39.28±0.76[3] 
 
All the determinations were carried out in triplicate and the values are expressed as the mean± SEM 
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INFERENCE: 
Invitro thymidine phosphorylase inhibitory activity was determined 
for the synthesized compounds, Ia-Ih at concentrations ranging from 10-
640 µg/ml. A dose dependent increase in percentage of inhibition to 
thymidine phosphorylase was observed for all the synthesized 
compounds. 
Compounds Ia-Ih exhibited varying degrees of thymidine 
phosphorylase inhibitory activity with IC50 values in the range of 23- 154 
µM when compared with standard drug 7- deazaxanthine having an IC50 
value of 39.28±0.76 µM. 
Compound Ig( IC50 = 23.36±1.160) and Ic (29.13±2.1) were found to 
be the most active members of the series , more potent than the standard.  
Compound Id ( IC50 =39.13± 3.5) and Ie (41.08± 3.2) also showed 
excellent anti- thymidine phosphorylase activity comparable with the 
standard. 
Compounds Ib and Ih showed IC50 values greater than 100 µM, 
therefore considered to be inactive. 
Activity of compound largely depends upon the substitution on 
aromatic ring attatched at the 2 nd position of 1,3,4 thiadiazole.Compound 
Ig with para nitro substitution on phenyl ring showed the highest degree  of 
thymidine phosphorylase inhibitory activity . 
Compound Ic with para chloro  substitution on phenyl ring and 
compound Id with with ortho and  para dichloro  substitutions on phenyl 
moiety  showed   IC50 value less than the standard. 
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The substitutions on position 4 of the phenyl ring appeared to be an 
important contributory factor to the inhibitory activity. 
Compound Ig was more potent than Ic suggested that greater 
electron withdrawing effect would lead to more active compounds. 
Therefore, the more electron withdrawing substituents inserted on para 
position of phenyl ring will result in more potent compounds. 
Substitution of chloro with nitro in the ortho, meta and para 
positions of phenyl ring resulted in increase in inhibitory activity. (Ie> Ia, If> 
Ib, Ig> Ic). 
Introduction of two nitro groups in the phenyl ring resulted in loss of  
activity. 
Introduction of chloro group in meta position also resulted in loss of 
activity. 
The order of potency of compounds was found to be Ig> Ic> Id> Ie> 
Ia> If> Ih> Ib. 
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ANTIMICROBIAL SCREENING 
APPARATUS AND CHEMICALS REQUIRED 
Hot air oven                                         :    Technico 
Incubator                                              :    Technico 
Autoclave                                             :     Kailash 
Horizontal laminar flow hood               :    CLEAN AIR instruments Inc. 
Petri dishes                                          :     SD Fine Chem Ltd 
Physical balance                                  :     Hrory (pvt) limited 
Micropipettes                                        :     VARI pipettes (Hi- Tab Lab) 
Microtips                                               :     Tarsons 
Conical flask(250 ml)                           :     Borosil 
Test tubes                                            :     Borosil 
Sterile swab                                         :     Hi media 
Nutrient broth                                       :     Hi Media 
Agar powder                                         :     Hi Media 
 The antibacterial screening were carried out in the Pharmaceutical 
Biotechnology Laboratory, College Of Pharmacy, SRIPMS, Coimbatore. 
 
 
 
 
SCREENING FOR ANTIBACTERIAL ACTIVITY[70,71] 
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Media : Mueller-  Hinton Agar 
Muller Hinton broth gelled by the addition of 2% agar 
(bacteriological grade) 
Ingredients 
Casein enzymatic hydrosylate     :  17.5 gm/L 
Beef infusion                                :   300 gm/L 
Soluble starch                              :  1.5 gm/L 
Final pH at 25° C                          :  7.4 ±0.2 
 Preparation  
            The ingredients were dissolved in distilled water with the aid of 
heat and pH was adjusted to 7.4±0.2 by using dilute acid or alkali. 
Sterilization 
15-30 ml of Mueller Hinton agar was transferred to petriplates and 
sealed. It was then  autoclaved at a pressure of 15 psi (1210C) for not less 
than 15 minutes. 
Microorganisms used 
Staphylococcus aureus NCIM 2079, Bacillus subtilis NCIM 2063, 
Escherichia coli NCIM 2918, Pseudomonas aeruginosa NCIM 2036 were 
procured from National Chemical Laboratory, Pune and stored in the 
Pharmaceutical Biotechnology Laboratory, College of Pharmacy,SRIPMS, 
Coimbatore. The strains were confirmed for their purity and identified by 
Gram’s staining method and their characteristic biochemical reactions. The 
selected strains were preserved by sub culturing periodically on nutrient 
agar slants and storing them under frozen conditions. For antimicrobial 
study fresh 24 hr cultures were used after the standardization of culture. 
Working conditions  
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The entire work was done by using horizontal laminar flow hood so 
as to provide aseptic conditions. Before the commencement of work air 
sampling was carried out using a sterile nutrient agar plate and exposing it 
to the environment inside the hood. After incubation it was checked for the 
growth of microorganism and absence of growth confirmed aseptic 
working condition. 
Preparation of Inoculam 
The inoculams for the experiment was prepared fresh in Mueller 
Hinton broth from preserved frozen slants. It was incubated at 37° C for 
18- 24 hrs and used after standardization. 
Standardization of Inoculums 
All the organisms were grown overnight (24 hours) at 370 C on 
nutrient agar and harvested during the stationary phase. Active cultures for 
experiments were prepared by transforming a loop full of cells from the 
stock culture to the test tubes containing Muller Hinton broth, incubated for 
24 hrs at 370C. Inoculum was standardized by matching the turbidity of the 
culture to 0.5 McFarland standard. The standard was produced by mixing 
0.5 ml of 0.048 BaCl2(1.175%w/v Barium chloride dehydrates) with 99.5 ml 
of 0.36N H2SO4. If the turbidity of culture matches that of McFarland 
standard, the culture inoculating suspension has approximately 2x106 
CFU/ml of bacteria. 
Drugs used                :  Synthesized drugs 
Standard drugs          :  Ciprofloxacin(5µg) 
Solvent                      :  Dimethyl sulfoxide 
 
ANTI- BACTERIA SCREENING BY KIRBY-BAUER METHOD[72] 
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Mueller Hinton agar was prepared aseptically to get a thickness of 
5-6 mm.The plates were allowed to solidify and inverted to prevent the 
condensate falling on the agar plate surface. The plates were dried at 
370Cbefore inoculation.The organisms were inoculated in the plates 
prepared earlier, by dipping a sterile swab in the previously standardized 
inoculums and excess of inoculums was removed by pressing and rotating 
the swab firmly against the sides of the culture tube above the level of 
liquid and finally streaking all over the surface of the medium three times, 
rotating the plates through an angle of 60° after each application. Finally 
the swab was pressed round the edges of agar surface. The plates was 
allowed to dry at room temperature, with the lid closed. The measured 
quantity of test drugs, standard and blank was poured in the wells, where 
the wells are made with the help of borer. The plates were kept in the 
refrigerator for 1 hour to facilitate the diffusion of the drugs. Plates were 
prepared in triplicate and they were incubated for 18-24 hours at 37°C. 
After the incubation, the diameter of the zone of inhibition for each drug 
was measured and compared with that of standard. All the synthesized 
compounds were tested for antibacterial activity against Gram positive and 
Gram negative bacteria. Saturated compounds of the solutions were first 
studied and then the compounds with zone of inhibition greater than 15 
mm were taken for quantitative studies. 
 
 
 
 
Table :3  QUANTITATIVE SCREENING OF TEST COMPOUNDS  FOR 
ANTIBACTERIAL ACTIVITY AGAINST  GRAM POSITIVE ORGANISMS 
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Sl.No 
Compound    
code 
Diameter of zone of inhibition in mm 
Staphylococcus aureus 
NCIM 2079 
Bacillus subtilis 
NCIM 2063 
500 µg/  ml 250 µg/ ml 
500 µg/ 
ml 
250 µg/ ml 
1 Ia 14 13 12 11 
2 Ib 15 14 15 14 
3 Ic 15 14 13 12 
4 Id 15 14 13 12 
5 Ie 14 12 12 11 
6 If 15 13 13 12 
7 Ig 15 13 14 12 
8 Ih 16 15 13 11 
9 Blank(DMF) - - - - 
10 
Standard 
Ciprofloxacin 
(5µg/ml) 
34 34 26 26 
 
 
Table :4 QUANTITATIVE SCREENING OF TEST COMPOUNDS  FOR 
ANTIBACTERIAL ACTIVITY AGAINST GRAM NEGATIVE ORGANISMS 
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Sl.No 
Compound    
code 
Diameter of zone of inhibition 
Escherichia coli  
NCIM 2918 
Pseudomonas 
aeruginosaNCIM 2036 
500 µg/ ml 
250 µg/ 
ml 
500 µg/ ml 250 µg/ ml 
1 Ia 15 12 13 12 
2 Ib 15 14 14 13 
3 Ic 14 13 13 12 
4 Id 18 12 15 13 
5 Ie 18 14 15 14 
6 If 19 15 13 12 
7 Ig 19 18 15 14 
8 Ih 14 13 18 16 
9 Blank(DMF) - - - - 
10 
Standard 
Ciprofloxacin 
(5µg/ml) 
32 32 33 33 
SCREENING OF SYNTHESIZED COMPOUNDS FOR ACTIVITY 
AGAINST GRAM POSITIVE ORGANISM 
Concentrations used            :   500 µg/ml and 250 µg/ml.   
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Standard drug                      :  Ciprofloxacin (5 µg/ml) 
Solvent used                        :   Dimethyl formamide 
Zone of inhibition of compounds against Staphylococcus aureus 
NCIM 2079 
  
                               
 
Zone of inhibition of compounds against Bacillus subtilis NCIM 2063 
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SCREENING OF SYNTHESIZED COMPOUNDS FOR ACTIVITY 
AGAINST GRAM NEGATIVE ORGANISM 
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Concentrations used            : 500 µg/ml.     
Standard drug                      : 5 µg/ml. 
Solvent used                        : Dimethyl formamide 
Zone of inhibition of compounds against Escherichia coli NCIM 2918 
 
 
 
 
Zone of inhibition of compounds against  
Pseudomonas aeruginosa NCIM 2036 
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DETERMINATION OF MINIMUM  INHIBITORY CONCENTRATION[73] 
 Compounds with good activity were selected for the determination 
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of minimum inhibitory concentration. 
Preparation of inoculums 
The inoculums for the experiment was prepared fresh in Mueller 
Hinton broth from the preserved frozen slant culture. It was incubated for 
18-24 hrs and used for the study after dilution to give 1:10 or 1:100 
dilutions. 
Standardization of inoculums 
The suspension of test organisms used was diluted to 1:100 after 
overnight incubation and standard drop(0.01 ml) was used for MIC 
determination. 
In vitro determination of MIC 
Invitro MIC determination of the test samples  was carried out by 
two fold serial dilution technique in Mueller Hinton broth for  
Staphylococcus aureus NCIM 2079, Bacillus subtilis NCIM 2063, 
Escherichia coli NCIM 2918, Pseudomonas aeruginosa NCIM 2036 .The 
concentration range of the compounds used were 5000- 78.15 µg/ml.  
Procedure 
 Test tubes were numbered as 1-8 and 1 ml of Mueller Hinton broth 
was added to each tubes. They were autoclaved at a pressure of 15 
psi at 121° C for not less than 15 minutes. 
 1 ml of diluted stock solution (5000 µg/ml) was added to the first 
test tube and serially transfer 1 ml up to the 7th  test tube to obtain 
the quantities indicated. 
 From the 7th test tube 1 ml was discarded. 
 The 8 th test tube was used as the control. 
 Diluted broth culture of test organism (0.01 ml) was added to all the 
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test tubes including  the control with a standard micropipette. 
 Mixed gently and incubated at 370 C for 16-18 hrs. 
 Results were observed. 
 The above procedure was carried out in duplicate. 
 The MIC was interpreted as the highest dilution of the test 
compound which showed clear fluid with no development of 
turbidity. 
 
Table:5 
Tube No. 1 2 3 4 5 6 7 Control 
Mueller 
Hinton 
broth(ml) 
1 1 1 1 1 1 1 1 
Drugs in 
serial 
dilution(ml) 
1 1 1 1 1 1 1 - 
Discard (ml) - - - - - - 1 - 
Culture 
Add 0.01 ml to each tube , Mix gently, kept in 
incubator for 16-18 hrs 
- 
Concentration 
(µg/ml) 
5000 2500 1250 625 312.5 156.25 78.15 - 
 
 
 
 
 
 
 
Table :6  SCREENING OF MINIMAL INHIBITORY CONCENTRATION    
FOR SAMPLE WITH GRAM POSITIVE BACTERIA (Staphylococcus 
aureus NCIM 2079) 
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Compound 
code 
Concentration(µg/ml) 
5000 2500 1250 625 312.5 156.25 78.15 
MIC 
values 
(µg/ml) 
Id - - - - - + + 312.5 
Ie - - - - + + + 625 
If - - - - - + + 312.5 
Ig - - - - - + + 312.5 
Ih - - - - + + + 625 
Control - - - - - - -  
Blank + + + + + + +  
 
Table :7 SCREENING OF MINIMAL INHIBITORY CONCENTRATION 
FOR SAMPLE WITH GRAM POSITIVE BACTERIA 
(Bacillus subtilis NCIM 2063) 
Compound 
code 
Concentration(µg/ml) 
5000 2500 1250 625 312.5 156.25 78.15 
MIC 
values 
(µg/ml) 
Id - - - - - + + 312.5 
Ie - - - - - + + 1250 
If - - - + + + + 312.5 
Ig - - - - + + + 625 
Ih - - - - - - + 156.25 
Control - - - - - - -  
Blank + + + + + + +  
(+) indicates turbidity 
(-) indicates clear 
 
Table :8 SCREENING OF MINIMAL INHIBITORY CONCENTRATION 
FOR SAMPLE WITH GRAM NEGATIVE BACTERIA 
(Escherichia coli NCIM 2918) 
 Antimicrobial Screening 
 
 
 
Department of Pharmaceutical Chemistry  102 
Compound 
code 
Concentration(µg/ml) 
5000 2500 1250 625 312.5 156.25 78.15 
MIC 
values 
(µg/ml) 
Id - - - - - + + 312.5 
Ie - - - + + + + 1250 
If - - - - + + + 625 
Ig - - - - - - + 156.25 
Ih - - - - - + + 312.5 
Control - - - - - - -  
Blank + + + + + + +  
Table : 9 SCREENING OF MINIMAL INHIBITORY CONCENTRATION 
FOR SAMPLE WITH GRAM NEGATIVE BACTERIA 
(Pseudomonas aeruginosa NCIM 2036) 
Compound 
code 
Concentration(µg/ml) 
5000 2500 1250 625 312.5 156.25 78.15 
MIC 
values 
(µg/ml) 
Id - - - - + + + 625 
Ie - - - + + + + 1250 
If - - - - + + + 625 
Ig - - - - + + + 625 
Ih - - - - - + + 312.5 
Control - - - - - - -  
Blank + + + + + + +  
(+) indicates turbidity 
(-) indicates clear 
 
In vitro MIC determination against Staphylococcus aureus NCIM 2079 
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                               Compound :Id               Compound: Ie 
 
 
 
 
 
 
 
  Compound: If                Compound: Ig  Compound: Ih 
 
 
 
 
 
In vitro MIC determination against Bacillus subtilis NCIM 2063 
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Compound  : Id Compound  : Ie  Compound  : If 
 
 
 
 
 
 
 
     Compound  : Ig          Compound  : Ih 
 
 
 
In vitro MIC determination against Escherichia coli NCIM 2918 
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Compound  : Id Compound  : Ie  Compound  : If 
 
 
 
 
 
 
 
 
       Compound  : Ig         Compound  : Ih 
 
 
In vitro MIC determination against Pseudomonas  
aeruginosa NCIM 2036 
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Compound  : Id   Compound  : Ie 
 
 
 
 
 
 
 
 
Compound  : If Compound  : Ig  Compound  : Ih 
 
SCREENING FOR ANTIFUNGAL ACTIVITY[74] 
Media - Sabouraud Dextrose Agar  
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 Ingredients 
Mycological peptone            :   10 gm 
Dextrose                              :   40 mg 
Agar                                     :   15 gm 
Water to make                     :   100 ml 
Final pH at 250C                  :   5.4±0.2 
 Preparation  
6.5 gm of Sabouraud dextrose agar was suspended in 1000 ml of 
distilled water and boiled to dissolve the medium completely. 
Sterilization 
15-30 ml of Sabouraud dextrose agar was transferred to petri plates 
and sealed. It was then autoclaved at a pressure of 15 psi (121°C) for not 
less than 15 minutes. 
Organisms used 
Candida albicans NCIM  3100  and  Aspergillus niger NCIM 596                 
Drugs used                 :   Synthesized drugs 
Standard drugs          :   Ketoconazole(10µg) 
Solvent                       :    Dimethyl sulfoxide 
 
 
ANTI- FUNGAL SCREENING BY KIRBY-BAUER METHOD 
           Sabouraud  Dextrose Agar  plates were prepared aseptically to get 
a thickness of 5-6 mm. The plates were allowed to solidify and inverted to 
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prevent condensate falling on the agar surface. The plates were dried at 
370Cbefore inoculation. 
                         The organisms (Candida albicans NCIM 3100 and 
Aspergillus niger NCIM 596) were inoculated in the plates prepared earlier, 
by dipping a sterile swab in the previously standardized inoculums and 
excess of inoculums was removed by pressing and rotating the swab 
firmly against the sides of the culture tube above the level of liquid and 
finally streaking the swab all over the surface of the medium three times, 
rotating the plates through an angle of 60° after each application. Finally 
the swab was pressed around the edges of agar surface. It was allowed to 
dry at room temperature, with the lid closed. The sterile disc containing 
test drugs, standard and blank were placed on the previously inoculated 
surface of Sabouraud dextrose agar plates. The plates were kept in the 
refrigerator for 1 hour to facilitate the diffusion of the drugs. 
              Plates were prepared in triplicate and they were incubated for 18-
24 hours at 250C.After the incubation, the diameter of the zone of inhibition 
around the drugs were measured and compared with that of standard. 
Eight of synthesized compounds were tested for antifungal activity. 
 
 
 
 
Table: 10   QUANTITATIVE SCREENING OF THE COMPOUNDS FOR 
ANTIFUNGAL ACTIVITY 
Sl No. Compound Diameter of zone of inhibition(mm) 
 Antimicrobial Screening 
 
 
 
Department of Pharmaceutical Chemistry  109 
code 
Candida albicans 
NCIM 3100 
Aspergillus niger 
NCIM 596 
100 µg/ disc 100 µg/disc 
1 Ia - 26 
2 Ib 12 27 
3 Ic 10 30 
4 Id 30 22 
5 Ie 10 11 
6 If 20 20 
7 Ig 24 23 
8 Ih 21 22 
9 Blank - - 
10 
Std 
Clotrimazole 
(10μg/disc) 
28 30 
(-) indicates no zone of inhibition. 
 
SCREENING OF SYNTHESIZED COMPOUNDS FOR ANTIFUNGAL  
ACTIVITY AGAINST  Candida albicans 
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SCREENING OF SYNTHESIZED COMPOUNDS FOR ANTIFUNGAL 
ACTIVITY AGAINST  Aspergilus niger 
 
 
 
 
 
 
 
 
 Results & Discussion 
 
 
 
Department of Pharmaceutical Chemistry  111 
RESULTS AND DISCUSSION 
Thymidine Phosphorylase Inhibitory activity. 
All the synthesized compounds were evaluated for in vitro thymidine 
phosphorylase inhibitory activity at concentrations ranging from 10-640 
µg/ml. A graded increase in the percentage of inhibition was observed with 
increase in concentration. The IC50 values were obtained by plotting 
percentage inhibition against concentration in µM. The values are 
compared with that of standard inhibitor 7- deazaxanthine. 
Compounds Ia-Ih exhibited varying degrees of thymidine 
phosphorylase inhibitory activity with IC50 values in the range of  
23- 154 µM. 
Compound Ig (IC50 = 23.36±1.160) and Ic (IC50 =29.13±2.1) were 
found to be the most active members of the series, more potent than the 
standard.  
Compound Id (IC50 =39.13± 3.5) and Ie (IC50 =41.08± 3.2) also 
showed excellent anti- thymidine phosphorylase activity comparable with 
the standard. 
The compounds Ia (IC50 = 63.63±3.6) and If ( IC50 =74.18±2.72) 
showed moderate anti- thymidine phosphorylase activity. 
Compounds Ib and Ih showed IC50 values greater than 100 µM, 
therefore considered to be inactive. 
Antibacterial activity 
All the newly synthesized compounds were screened for 
antibacterial activity against both Gram positive and Gram negative 
organisms using Ciprofloxacin (10 µg/ml) as the standard. .  
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 The newly synthesized compounds Ia, Ib, Ic, Id, Ie, If ,Ig, Ih were 
moderately sensitive against the test microorganism Staphylococcus 
aureus NCIM 2079 at 500 µg/ml concentration. The compound Ih exhibited 
the highest activity. 
The compounds Ia, Ib, Ic, Id, Ie, If, Ig, Ih were moderately sensitive 
against the test microorganism Bacillus subtilis NCIM 2063 at 500 µg/ml 
concentration. The compound Ib exhibited the highest activity. 
The compounds Id, Ie, If, Ig were sensitive and compounds Ia, Ib, 
Ic, Ih were moderately sensitive against the test microorganism 
Escherichia coli NCIM 2918 at 500 µg/ml concentration. The compounds If 
and Ig exhibited the highest activity. 
The compound Ih  were sensitive and compounds Ia, Ib, Ic, Id ,Ie, If, 
Ig were moderately sensitive  against the test microorganism 
Pseudomonas aeruginosa NCIM 2036 at 500µg/ml concentration. The 
compound Ih exhibited the highest activity. 
Minimum Inhibitory Concentration 
The MIC values for the potent compound Id, Ie, If, Ig and Ih were 
determined for the test organisms Staphylococcus aureus NCIM 2079,  
 Bacillus subtilis NCIM 2063, Escherichia coli NCIM 2918 and  
Pseudomonas aeruginosa NCIM 2036. 
For Staphylococcus aureus NCIM 2079, compound Ig, If and Id  
showed the lowest  MIC value (312.5 µg/ml) whereas for Bacillus subtilis 
NCIM 2063, compound Ih  showed  the lowest MIC values(156.25 µg/ml)  . 
For Escherichia coli NCIM 2918, compound Ig showed the lowest  
MIC value(156.25µg/ml) whereas for Pseudomonas aeruginosa NCIM 
2036,compound Ih showed the lowest MIC value (312.5 µg/ml) . 
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Antifungal activity  
All the newly synthesized compounds were screened for antifungal  
activity against Candida albicans NCIM 3100 and Aspergillus niger NCIM 
596  by agar disc  diffusion method  using Fluconazole  (10 µg/ disc) as 
the standard. 100 µg/ disc was used for all the test compounds. 
The compounds Id, If, Ig and Ih  were sensitive and compounds Ib, 
Ic were moderately sensitive and compounds Ia and Ie are resistant  
against Candida albicans NCIM 3100 at 100 µg/ disc  concentration. The 
compounds Id exhibited the highest activity. 
The compounds Ia, Ib, Ic, Id,,If, Ig and Ih  were sensitive and 
compound Ie   was resistant  against Aspergilus niger NCIM 596 at 100 
µg/ disc  concentration. The compounds Ic exhibited the highest activity. 
Table: 11     ANTIBACTERIAL ACTIVITY OF SYNTHESIZED 
COMPOUNDS AT 500 µg/ disc AND ANTIFUNGAL ACTIVITY AT  
100 µg/disc. 
Sl 
No. 
Compound 
code 
Microorganism 
Zone of 
Inhibition 
Report 
1 Ia 
Staphylococcus 
aureus 
14 
Moderately 
sensitive 
Bacillus subtilis. 12 
Moderately 
sensitive 
Escherichia coli 15 
Moderately 
sensitive 
Pseudomonas 
aeruginosa 
13 
Moderately 
sensitive 
Candida albicans - Resistant 
Aspergillusniger 26 Sensitive 
2. Ib 
Staphylococcus 
aureus 
15 
Moderately 
sensitive 
Bacillus subtilis. 15 
Moderately 
sensitive 
Escherichia coli 15 
Moderately 
sensitive 
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Sl 
No. 
Compound 
code 
Microorganism 
Zone of 
Inhibition 
Report 
Pseudomonas 
aeruginosa 
14 
Moderately 
sensitive 
Candida albicans 12 
Moderately 
sensitive 
Aspergillusniger 27 Sensitive 
 
 
3 
 
 
Ic 
Staphylococcus 
aureus 
15 
Moderately 
sensitive 
Bacillus subtilis. 13 
Moderately 
sensitive 
Escherichia coli 14 
Moderately 
sensitive 
Pseudomonas 
aeruginosa 
13 
Moderately 
sensitive 
Candida albicans 10 Resistant 
Aspergillusniger 30 Sensitive 
4 
 
Id 
 
Staphylococcus 
aureus 
15 
Moderately 
sensitive 
Bacillus subtilis. 13 
Moderately 
sensitive 
Escherichia coli 18 Sensitive 
Pseudomonas 
aeruginosa 
15 
Moderately 
sensitive 
Candida albicans 30 Sensitive 
Aspergillusniger 22 Sensitive 
5 
 
 
Ie 
Staphylococcus 
aureus 
14 
Moderately 
sensitive 
Bacillus subtilis. 12 
Moderately 
sensitive 
Escherichia coli 18 Sensitive 
Pseudomonas 
aeruginosa 
15 
Moderately 
sensitive 
Candida albicans 10 Resistant 
Aspergillusniger 11 Resistant 
 
 
6. 
 
 
If 
Staphylococcus 
aureus 
15 
Moderately 
sensitive 
Bacillus subtilis. 13 
Moderately 
sensitive 
Escherichia coli 19 Sensitive 
Pseudomonas 
aeruginosa 
13 
Moderately 
sensitive 
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Sl 
No. 
Compound 
code 
Microorganism 
Zone of 
Inhibition 
Report 
Candida albicans 20 Sensitive 
Aspergillusniger 20 Sensitive 
 
 
7 
 
 
Ig 
Staphylococcus 
aureus 
15 
Moderately 
sensitive 
Bacillus subtilis. 14 
Moderately 
sensitive 
Escherichia coli 19 Sensitive 
Pseudomonas 
aeruginosa 
15 
Moderately 
sensitive 
Candida albicans 24 Sensitive 
Aspergillusniger 23 Sensitive 
 
8 
 
Ih 
Staphylococcus 
aureus 
16 
Moderately 
sensitive 
Bacillus subtilis. 13 
Moderately 
sensitive 
Escherichia coli 14 
Moderately 
sensitive 
Pseudomonas 
aeruginosa 
18 Sensitive 
Candida albicans 21 Sensitive 
Aspergillusniger 22 Sensitive 
 
Zone diameter  :  18 and above- Sensitive 
  12-17- Moderately sensitive 
  <12- Resistant 
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SUMMARY AND CONCLUSION 
 
The present work was focused on synthesis, thymidine 
phosphorylase inhibitory activity  and  antimicrobial screening of  eight 
different Schiff bases of 7- hydroxyl- 3- formyl chromone with 2-amino 5-aryl 
1,3,4- thiadiazole.. 
LITERATURE REVIEW 
The extensive literature review reports showed that  Schiff bases of 
3- formyl chromone  are potent thymidine phosphorylase inhibitors  and the 
chromone moiety, thiadiazole and Schiff bases posses excellent 
antimicrobial activity. 
SYNTHESIS 
In the present work a total of eight new Schiff bases of 3- formyl 
chromone were synthesized. 
Scheme 
Step I 
7- hydroxyl 3- formyl chromone were synthesized from 2,4- dihydroxy 
acetophenone using Vilsmeier Haack reaction . 
Step II 
Eight different 2- amino 5- aryl 1,3,4 thiadiazoles  were prepared from 
thiosemicarbazide and  various aryl carboxylic acid in presence of 
conc.sulphuric acid. 
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Step III 
Schiff bases were synthesized from 7- hydroxyl 3- formyl chromone 
dissolved in methanol  and various  2- amino 5- aryl 1,3,4 thiadiazoles in 
presence of conc. sulphuric acid. 
CHARACTERIZATION 
Melting points of all the newly synthesized compounds were 
determined. Rf values were determined on precoated silicagel –G plates by 
using suitable solvent systems. Structures of the compounds were 
confirmed by UV, IR, PMR and Mass spectral data. Yields of derivatives 
were in the range of 74-86%. 
BIOLOGICAL STUDIES 
THYMIDINE PHOSPHORYLASE INHIBITORY ACTIVITY 
All the newly synthesized compounds were screened for in-vitro 
thymidine phosphorylase inhibitory activity. Compounds Ig  and Ic  were 
found to be the most active members of the series , more potent than the 
standard. Compounds Id  and Ie  also showed excellent anti- thymidine 
phosphorylase activity comparable with the standard.   
ANTIBACTERIAL ACTIVITY 
Eight of newly synthesized compounds were screened for their anti 
bacterial activity against Bacillus subtilis, Staphylococcus aureus, Escheria 
coli and Pseudomonas aeruginosa by agar cup plate method at 
concentrations of 500 µg/ml and 250 µg/ml. 
Among the compounds, Ih showed maximum activity against 
Staphylococcus aureus and Pseudomonas aeruginosa and Ib showed 
highest activity against Bacillus subtilis. In the case of Escherichia coli, 
compounds If and Ig showed highest activity.  
 Summary & Conclusion 
 
 
 
Department of Pharmaceutical Chemistry  118 
The compound Ih showed the lowest MIC values of 156.25 and  
312.5 µg/ml for Bacillus subtilis and Pseudomonas aeruginosa  respectively. 
For Staphylococcus aureus, compounds Id, Ig and If showed the lowest MIC 
values (312.5 µg/ ml). Compound Ig showed the lowest MIC value of 156.25 
µg/ ml for Escherichia coli.   
ANTIFUNGAL SCREENING 
All the newly synthesized compounds were screened for antifungal  
activity against Candida albicans NCIM 3100 and Aspergillus niger NCIM 
596  by agar diffusion method  using Fluconazole  (10 µg/disc) as the 
standard. 100 µg/ disc was used for all the test compounds. 
The compound Id and Ic exhibited the highest activity towards 
Candida albicans and Aspergillus niger respectively. 
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CONCLUSION  
Based on the results of synthetic works, characterization data, 
enzyme inhibition studies and antimicrobial screening, the following 
conclusions were made. 
 Using the schemes evolved, eight different Schiff bases of  
 7-hydroxy -3- formyl chromone were synthesized in good yields. 
 The in vitro thymidine phosphorylase inhibitory activity studies 
indicated that compounds Ig and Ic showed excellent inhibitory 
activity against thymidine phosphorylase, more potent than standard. 
The compounds Id and Ie also showed inhibitory activity comparable 
with the standard. A general trend showed that more electron 
withdrawing substituents inserted on para position of phenyl ring will 
result in more potent compounds. 
 The in vitro antimicrobial studies showed that all the compounds 
exhibited good antibacterial and anti fungal activity in which 
compound Ih showed the  highest activity against  Staphylococcus 
aureus and Pseudomonas aeruginosa.  Ib, If and Ig showed highest 
activity against Bacillus subtilis and Escherichia coli respectively. The 
compound Id and Ic exhibited the highest anti fungal activities. 
 Of the 8 compounds synthesized, Ig, Ic and Id can be chosen as lead 
moieties for the development of  effective thymidine phosphorylase 
inhibitors. Similarly Ih and Id can be taken up for the development of 
ideal anti bacterial and anti fungal agents respectively. 
